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ABSTRACT
Doty, Heather Alisa, PhD. The University of Memphis. December 2015. Dual Drug
Delivery With Calcium Sulfate-Chitosan Based Scaffolds For Bone Regeneration And
Infection Control. Major Professor: Dr. Joel D. Bumgardner.
The incidence of infection and non-union in severe musculoskeletal fractures
continues to plague the medical community. This work investigated calcium sulfate (CS)chitosan composite scaffolds with dual drug delivery capabilities. The aim of this
dissertation is to investigate potential strategies for a dual delivery composite scaffolds
that will allow for sufficient delivery of two therapeutic agents to control infection and
regrow bone.
Initial work focused on a chitosan microspheres-composite for delivery of antibiotics
and growth factors. The dual delivery of antibiotics from both the CS and chitosan
components was an approach to treat polymicrobial infections, while the dual delivery of
an antibiotic from CS and growth factor from the chitosan component was aimed at bone
regeneration to treat fractures that require additional therapies to stimulate bone healing
while preventing an infection. The effectiveness of the dual antibiotic loaded scaffold to
eliminate infection was depended on the amount of drugs loaded and if the drugs were
delivered together or separate. Vancomycin released from the dual loaded scaffold
sustained almost 5 weeks of bacterial growth inhibition, whereas the amikacin release
inhibited bacterial growth for only one day. The composite scaffold loaded with
vancomycin and a growth factor, rhBMP-2, had extended bacterial inhibition and killing.
The rhBMP-2 release was delayed 2 days and had a low-level extended elution over 6
weeks. The activity of rhBMP-2 could not be determined, and it was found that the level
of rhBMP-2 released might not have been high enough to stimulate cells in vitro. To
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increase the rhBMP-2 elution, mechanical integrity, and make channels for
vascularization ingrowth, chitosan meshes were substituted for the microspheres in the
third study. While the meshes increased the vancomycin elution, no change in rhBMP-2
elution was found. The meshes did improve the ability of the scaffold to remain intact
under mechanical forces.
While further research into the biological activity of released rhBMP-2 and in vivo
evaluation of the scaffold must be performed, our research demonstrates the successful
dual delivery of therapeutic agents from a composite scaffold that could be used as an
adjunctive therapy for infected musculoskeletal fractures.
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PREFACE
The purpose of this research was to develop and evaluate a novel composite scaffold
with drug delivery capabilities for use in severe musculoskeletal fractures. The work
presented in this dissertation is comprised of manuscripts, which are published or will be
submitted for publications. The following manuscripts make up the main body of this
dissertation:

Chapter 2:
“Elution of amikacin and vancomycin from a calcium sulfate/chitosan bone scaffold”.
Biomaterials and Biomedical Engineering. (2015); 2(3), 159-172.
Chapter 3:
“Composite chitosan and calcium sulfate scaffold for dual delivery of vancomycin and
recombinant human bone morphogenetic protein-2”. Journal of Material Science.
Materials in Medicine. (2014); 25(6), 1449-1459.
Chapter 4:
“Evaluation of a calcium sulfate-chitosan fiber-mesh scaffold as a dual
delivery bone scaffold for rhBMP-2 and vancomycin ”. Planned submission
to Biomaterials Science.
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CHAPTER 1
INTRODUCTION

Background
Traumatic bone fractures, birth defects, bone tumor removal, or other large
musculoskeletal wounds, can be difficult for the body to heal on its own. Often surgeries
and medical interventions, such as bone grafts, are necessary due to large bone voids and
lack of sufficient vasculature and blood flow to the wound [1,2]. In the US alone over 8
million bone fractures occur each year and over 1 million surgeries are performed to treat
severe orthopaedic traumas including bone excisions, grafting and fracture repair [3,4].
The economic burden of musculoskeletal treatments in 2004, including hospital costs,
and salary loss was estimated at $26.65 billion/year, and is increasing every year due to
the aging population and continued military engagements [1,5].
Complex musculoskeletal injuries can become infected with a variety of pathogenic
bacteria at the time of injury, during surgery or in the hospital [6–8]. Infections can
impair healing, lead to repeated surgeries, result in sepsis, limb amputation, and even loss
of life [9–13]. Open fractures are particularly sensitive to infection and occur when skin
and soft tissue are significantly damaged and expose the wound to the surrounding
environment [14–16]. While the reported rates of infection from internal fixation devices
are 2%-5%, infection in open fractures typically varies from 20-65% [2,17–19].
Additionally, the majority of combat extremity wounds are open fractures [11], and they
are often plagued with non-union and rates of infection up to 77% [20].
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Pathogens commonly responsible for infections in musculoskeletal injuries include
both Gram-positive and Gram-negative bacteria such as Pseudomonas aeruginosa (P.
aeruginosa), Escherichia coli, Staphylococcus epidermidis and Staphylococcus aureus
(S. aureus) [21–24]. Chronically infected fractures are more difficult to treat, and can be
at greater risk for polymicrobial infections, where one or more bacterial or fungal species
are present [21,25]. Similarly, an increase in combat related polymicrobial infections has
been seen due to drug resistance in bacteria such as methicillin-resistant S. aureus
(MRSA) [20,25]. Thus, there is a critical need for therapies that can treat and prevent
musculoskeletal wounds from single and polymicrobial infections to improve patient
outcomes and reduce the economic burden.
Current treatment strategies for traumatic bone injuries include irrigation and
debridement to help remove infectious agents, foreign bodies and necrotic tissue, wound
stabilization and closure, and administration of systemic antibiotics [12,13,19,26–28].
Normal bone healing occurs in stages; first a blood clot is formed, then inflammation
occurs, next a soft callus is formed which is transformed into bony callus, and overtime
this callus is remodeled into bone [13,29,30]. If any one of these repair phases is
inhibited, fracture healing will be delayed or prevented, resulting in a non-union [29,30].
In traumatic musculoskeletal injuries, severely damaged vasculature affects the normal
healing pathway by blocking the transport of cells to the wound, and it will also inhibit
the delivery of systemic antibiotics which subsequently increases the chances of an
infection in the wound [2,31,32]. Additionally, if the bone defect is too large, cells will
not be able to mitigate the healing process and regeneration will not occur. Thus, when
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the musculoskeletal tissue damage is severe, adjuvant therapies such as delivery of local
antibiotics and growth factors in a bone graft may be necessary [2,12,13,19].
An ideal bone graft material for the treatment of large fractures should be
biocompatible, bio-resorbable, osteoconductive, able to maintain a 3D structure for
cellular support, easy to use, cost effective, and a suitable carrier for multiple different
therapeutic agents [1,33,34]. Bone grafts for this purpose have been developed from
primarily two types of materials: ceramics and degradable polymers.
Ceramic materials such as calcium phosphate (CPC), hydroxyapatite (HA) and
calcium sulfate (CS) have been extensively studied as drug delivery devices for infection
control in fractures [1,2,35]. They are osteoconductive, biodegradable, readily available,
inexpensive and can be manufactured into a variety of shapes or be made injectable when
used in combination with other materials [1,36]. Calcium phosphates are relatively brittle
and can take 26-86 weeks to absorb into the body [1,35]. While calcium sulfate materials
are sometimes associated with wound drainage, it has not been reported to prevent
healing [37,38]. Additionally, calcium sulfates have a fast resorption rate of 4-12 weeks
and excellent drug delivery capabilities making it a good candidate for a graft material in
fracture repair [35,39].
Calcium sulfate (CS) is a naturally occurring mineral, gypsum, and through a drying
process called calcination it is converted to CS hemihydrate form [40,41]. With the
addition of water, CS is converted back to a dehydrate configuration and through a mild
exothermic reaction sets into a hardened form. !"!"! ∙ 1 2 !! ! + 1 1 2 !! ! ↔
!"!"! ∙ 2!! !. There are two forms of CS hemihydrate: α, the densest form is used in
medical applications, and β, a less dense form that requires more water for conversion is
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commonly used for commercial materials. CS has been used as a bone filler since 1892
and was first approved by the Food and Drug Administration as a surgical graded calcium
sulfate called “Osteoset” in 1996 [37,40]. CS was reported by Ricci et al. to leave behind
an apatite “bioactive lattice” upon degradation upon which bone cells can attach and
proliferate in vivo. Additionally, it has been reported that calcium ions may aid in
osteoblastic differentiation [40,41]. CS has been extensively studied in vitro and in vivo
and is an effective antibiotic delivery system for compounds such as amikacin,
vancomycin, tobramycin, gentamicin, cefazolin and rifampicin [41–47].
Polymers offer a variety of advantages in tissue engineering and have been widely
investigated as local drug delivery systems [2,19,48–50]. There are two main classes of
degradable polymers, synthetic and natural. Synthetic polymers such as poly(lactic acid)
(PLA), poly(lactic-co-glycolic acid) (PLGA), poly(e-caprolactone) (PCL),
polyhydroxyalkanoates, polyurethane (PUR) and poly(2-hydroxyethy methacrylate)
(pHEMA) have many variables that can be adjusted during manufacturing to achieve
desired properties [2,19,48]. Thus, they have been used in drug delivery to achieve
optimal loading and delivery. PLA, PLGA and PUR based scaffolds have been shown to
deliver stimulatory amounts of bone morphogenetic protein-2 (BMP-2) to repair bone
defects in vivo [19,51]. Additionally PLGA, pHEMA and PUR based scaffolds have been
reported to release active levels of antibiotics (tobramycin, doxycycline, gentamicin and
vancomycin) for 2-8 weeks in vitro and in vivo [19,52–55]. While synthetic polymers
offer customizable drug release kinetics they often lack the structural integrity needed for
bone scaffolds, the ability to promote bone healing and can have weak interactions with
bone tissue, causing graft rejection and inflammation [2,19,28,48,50]. Therefore,
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synthetic polymers are often used in combination with ceramic materials and growth
factors to overcome these limitations [19,48–50].
Unlike synthetic polymers, natural polymers such as collagen, fibrin, chitosan and
alginate have the advantage of being easily recognized by the body, and supporting
cellular adhesion and proliferation [2]. However, as stand-alone bone graphs, natural
polymers are also typically not strong enough to be used in a large bone defect, can be
limited in supply and have some consistency issues between batches [35,56]. The medical
device InFUSE® uses a collagen sponge in combination with a titanium cage to delivery
BMP-2 for enhanced bone regeneration in the spine [31,49,57]. As a result of the
supraphysiological doses typically used in collagen sponges to elicit the necessary in vivo
tissue responses, negative side effects such as uncontrolled bone growth and ectopic bone
growth in an unwanted area are a major concern [49,58]. Thus, delivery kinetics should
be manipulated to achieve the desired elution effect with reduced side effects for any
bone scaffold system. Chitosan is one natural polymer that has been extensively studied
due to its customizability for drug delivery applications [59–64].
Chitosan is the deacetylated product of the natural biopolymer chitin, a
polysacharride found primarily in the exoskeleton of shellfish. When more than 50% of
the acetyl groups are removed from chitin, the polymer is considered to be chitosan and is
composed of both acetylated and deacetylated β -(1-4)-2-amino-2-D-glucosamine units
[60,65,66]. The degree of deacetylation (DDA), molecular weight (MW) and
crystallinity, can be used to control the rate of degradation and chitosan can be easily
manipulated into a variety of forms such as microbeads, nanobeads, fibers, meshes, and
sponges [60,65–68]. Chitosan is also biocompatible, supporting cellular growth and
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function, and can be used as a drug delivery device for many therapeutic factors
[60,62,69–72]. Since the mechanical strength of chitosan (in any form) is much less than
of cancellous bone (10-2000 MPa) it is not ideal as a stand-alone device for large
musculoskeletal fractures [73].
Many different chitosan-ceramic composites have been investigated. Chitosan
sponges, fibers, meshes, gels and microspheres have been incorporated with calcium
phosphate, hydroxyapatite and calcium sulfate materials [63,71,74–79]. In vitro, CPCchitosan composites have been reported to facilitate proliferation and differentiation of
bone cells [71,75,80]. Additionally, several studies have found that the addition of
chitosan (sponge, fiber, meshes) into ceramic materials also improves the mechanical
strength of the bone grafts [75,81–84]. In rabbit and dog models CPC–chitosan, HAchitosan and CS-chitosan grafts showed good tissue ingrowth and bone repair
[77,83,85,86]. Although these composite scaffolds have shown good biocompatibility, in
an infected musculoskeletal wound there is an additional need to fight infection and
promote bone regeneration.
Bone grafts that are also able to locally deliver therapeutic agents can inhibit bacterial
colonization independent of circulation and have no associated organ toxicity as seen
with high doses of systemic antibiotics [15,51,87]. Additionally, developing a graft that
can be prepared and loaded with therapeutic agents in the operation room allows for
tailored treatment specific to the patient. This customization is beneficial because
fractures can be infected with a variety of both Gram-positive and Gram-negative
bacteria [15,22,25]. In patients that present polymicrobial infections, treatment strategies
with two or more antibiotics may be necessary. While many types of antibiotics are used
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to treat orthopaedic infections, amikacin and vancomycin are of particular interest
because they have both shown low toxicity on osteogenic cell viability and activity
[20,21,88,89]. Amikacin is a broad-spectrum antibiotic that is active against Gramnegative and Gram-positive bacteria, and the antibiotic vancomycin, is active against
Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA),
which poses a severe threat to fracture healing [20,90]. The co-delivery of amikacin and
vancomycin from calcium sulfate and a polymer gel has been studied [91,92]. Atilla et al.
found that when antibiotics were combined in one calcium sulfate pellet, the elution rate
was much higher, and the effectiveness against bacteria had a shorter duration as
compared to single loaded pellets. They suggested this was due to increased porosity in
the CS when both antibiotics were used [91]. Conversely, Thomas et al. reported slower
and extended elution of vancomycin, amikacin and clindamycin from a R-gel polymer.
They found the eluents were bioactive against S. aureus during a 10 day study [92]. No
loss in activity was found for either antibiotic when co-delivered, indicating that
amikacin and vancomycin could be used together to treat Gram-positive and Gramnegative polymicrobial infections [91,92]. However, the elution and activity duration
reported is shorter than the recommended 4-6 weeks duration of local delivery, based on
the time it takes for revascularization of bone in animal studies [2,93,94]. Thus, a bone
graft that could control and extend the dual antibiotic elution over a longer period of time
is needed.
Bone formation and regeneration is tightly regulated by three groups of signaling
molecules 1) pro-inflammatory cytokines 2) transforming growth factor-beta superfamily
members and 3) angiogenic factors [30]. Bone morphogenetic proteins (BMP) are
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members of the transforming growth factor-beta family that initially recruit stem cells to
the fracture site where they initiate blood vessel formation and differentiation of stem
cells into osteoblasts [30,95–97]. There are currently about 15 identified members of the
BMP family [96]. Both BMP-2 and BMP-7 are commonly studied for fracture repair.
BMP-2 initially recruits cells and acts later during osteogenesis and chondrogenesis,
whereas BMP-7 acts only on bone differentiation [2]. Since BMP-2 is active through the
stages of healing, studies have shown that the extended delivery of BMP-2 is more
effective than an initial bolus release [58,96,98,99]. A drawback of current BMP-2 use is
that often supraphysiological doses are needed to compensate for poor release kinetics,
fast inactivation in vivo, and lack of extended delivery of biological active growth factor
[49,58]. These high doses have been associated with adverse reactions such as excessive
bone formation, ectopic bone formation, and due to the expense of BMP, high doses
greatly increase the cost of treatment [97,100,101]. Combination delivery devices that
can optomize the BMP-2 delivery could be a solution to overcome these limitations.
The local delivery of both a growth factor and an antibiotic in a bone graft is
attractive for use in complex musculoskeletal fractures. Studies have shown that when
co-delivered from polymers, polymer coating on a K-wire or in CS, BMP-2 remained
active in the presence of an antibiotic [51,53,102–104]. Similarly, in vivo results have
indicated that BMP-2 and an antibiotic co-delivered from collagen sponges, a CS
scaffold, and polymers is effective in augmenting new bone formation between 4-12
weeks [51,102,103,105]. Guelcher et al. investigated a PUR scaffold loaded with both
vancomycin and BMP-2 in vivo. The most significant bone growth in the rat femoral
defect was found from scaffolds loaded with both BMP-2 and vancomycin, compared to
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BMP-2 loaded scaffolds or controls. This indicated that in the presence of infection, new
bone regeneration was inhibited [58]. While these studies report that co-delivery of
antibiotics with growth factors can result in bone healing and infection control, some
required a supraphysiological dose of BMP [102], lack the ability to customize the
scaffold in the operating room [51,53,103], and had unpredictable degradation rates that
could interfere with bone regeneration [53,58,105]. The use of a composite ceramicdegradable polymer bone graft may help to overcome these limitations.
Hypothesis
Currently, there is a clinical need for a dual drug delivery bone scaffold to have 1)
good drug release kinetics for extended therapeutic activity and reduced side
effects/expense, 2) degradation rates similar to bone growth, 3) the ability to maintain 3D
space, and 4) the flexibility of preparation and customization by the surgeon for
individualized treatment. In this dissertation, we investigated in vitro the dual delivery of
two antibiotics and the combination of a growth factor and an antibiotic from a composite
calcium sulfate-chitosan based scaffold with the aim of extended antibiotic and growth
factor elution for infection control and cellular indication of active growth factor.
Optimization of growth factor delivery was pursued with the use of both chitosan
microspheres and wet-spun fiber-meshes. The scaffolds were designed with the idea that
they could be used as a point-of-care devices, could be customized drug delivery system
loaded with a variety of therapeutic agents, and would eliminate the need for
supraphysiological doses of growth factor. Additionally, the materials for this scaffold
were chosen because they have the ability to maintain a 3D structure where bone cells
can attach and lay down new bone matrix, and they have good degradation properties.
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Our overall hypothesis is that composite calcium sulfate-chitosan scaffolds will be able to
meet the clinical needs for dually delivering therapeutic agents for infection control and
bone regeneration.
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CHAPTER 2
ELUTION OF AMIKACIN AND VANCOMYCIN FROM A CALCIUM
SULFATE/CHITOSAN BONE SCAFFOLD

1. Introduction
Infections in complex orthopaedic wounds can delay or inhibit healing and can be very
difficult to treat (Thomas et al. 2005; Noel et al. 2010; Nair et al. 2011). Together,
infection and severe tissue damage can reduce blood flow, which can prevent the
necessary inflammatory and reparative cells from accumulating and acting at the wound
site (Nair et al. 2011). Reported infection rates after surgery and trauma range from 155% and open fracture infections range from 10-50% depending on the severity of the
wound (Patzakis and Wilkins 1989; Jain and Panchagnula 2000; Zalavras et al. 2005;
Anderson et al. 2011; Wenke and Guelcher 2011; Hogan et al. 2013). Common
pathogens responsible for infecting these injuries include both Gram-positive and Gramnegative bacteria such as Pseudomonas aeruginosa, Escherichia coli, Staphylococcus
epidermidis and Staphylococcus aureus (Gentry 1997; Kobayashi et al. 2008;
Hatzenbuehler and Pulling 2011; Hogan et al. 2013). Treatment can be particularly
challenging in wounds containing polymicrobial bacterial species and/or resistant species
such as methicillin-resistant S. aureus (MRSA). In addition, identifying the infecting
organism is time-consuming and can be misleading when results are falsely negative
(Brady et al. 2006; Kobayashi et al. 2008; Hogan et al. 2013; Parvizi et al. 2014).
Polymicrobial orthopaedic infections may require more than one antibiotic for
sufficient treatment. Local delivery devices loaded with antibiotics have been
investigated due to toxicity issues with systemic delivery and reduced vasculature in the
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wound (Zilberman and Elsner 2008; Noel et al. 2010; Rathbone et al. 2011; Schlickewei
et al. 2014), but only a handful of dual delivery systems have been reported
(Lodenkämper et al. 1982; Penner et al. 1996; Bucholz 2002; Phillips et al. 2007; Atilla et
al. 2010; McPherson et al. 2013; Sakamoto et al. 2013; Howlin et al. 2015). A dualantibiotic-loaded local delivery device made from polymethylmethacrylate (PMMA) was
investigated by Penner et al. and Phillips et al. and found to have a much faster rate of
elution than the single antibiotic loaded devices (Penner et al. 1996; Phillips et al. 2007).
Although PMMA has been used to deliver antibiotics, it is not an ideal delivery device
since it requires additional surgery for removal, can only be used with certain heat-stable
antibiotics, and can elute low-level antibiotics that contribute to bacterial resistance.
The limitations of PMMA have resulted in ongoing research on degradable drug
delivery systems, such as calcium sulfate, which can be loaded with a wider variety of
antibiotics than PMMA (McLaren 2004; Wenke et al. 2006; Gogia et al. 2009; Thomas
and Puleo 2009; McConoughey et al. 2015). Amikacin and vancomycin were codelivered from a degradable calcium sulfate scaffold by Atilla et al. (Atilla et al. 2010).
They reported results similar to PMMA studies; faster elution with the dual-loaded
scaffold compared to single loaded scaffolds. The fast elution rates of dual-loaded
scaffolds may be considered a shortcoming for local delivery systems because of a loss of
long-term antibiotic and therapeutic effectiveness. The reason for the fast elution rate of
dual-loaded scaffolds is not clear. Speculations from literature are that the presence of
two antibiotics results in an increased porosity of the scaffold and allows for faster
elution through the pores, and/or that the potential for chemical interactions between the
antibiotics and the scaffold may increase scaffold degradation rates leading to faster
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antibiotic release (Penner et al. 1996; Phillips et al. 2007; Atilla et al. 2010).
Additionally, high levels of antibiotic incorporation can interfere with complete
conversion of calcium sulfate to the dehydrate form, possibly causing faster degradation
and faster antibiotic elution (Richelsoph et al. 2007; Thomas and Puleo 2009; Atilla et al.
2010). Regardless of the reason, current research reports that dual-loaded scaffolds elute
antibiotics faster than scaffolds with a single antibiotic. However, extending local
antibiotic administration for 4-6 weeks is desired to completely eradicate and prevent
serious infections. This time frame comes from clinical studies with antibiotic therapy
and the time necessary for revascularization of bone in animal studies (Lew and
Waldvogel 1997; Lazzarini et al. 2004; Nair et al. 2011). Additionally, polymicrobial
infections may require more than one antibiotic for treatment. Thus, there is a need for a
scaffold system that can deliver two antibiotics with extended elution times while
retaining necessary properties to support new bone growth.
To address the extended dual-delivery problem, a scaffold composed of antibioticloaded chitosan-nano hydroxyapatite (C-nHA) microspheres embedded into antibioticloaded calcium sulfate (CaS) paste was investigated. Calcium sulfate was chosen because
it is a commercially used bone graft material, has the versatility to be loaded with
multiple different antibiotics, can be manipulated by the surgeon at the point of care, and
can easily act as a binder for other materials such as microspheres (Wichelhaus et al.
2001; Thomas et al. 2005; Richelsoph et al. 2007; Thomas and Puleo 2009; Parker et al.
2011). Drug-loaded C-nHA microspheres were selected because they have been shown to
be effective for local drug delivery, and they may also be easily incorporated into other
materials such as CaS paste, which can act as a temporary barrier to fluid flow from the
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surrounding environment and slow/extend drug release from the microspheres (Pecora et
al. 1997; Thomas and Puleo 2009; Reves et al. 2009; Doty et al. 2014). The C-nHA
microspheres may also provide a necessary framework for tissue regeneration, since a
limitation of calcium sulfate is a fast resorption rate (Chesnutt et al. 2009; Thomas and
Puleo 2009; Dash et al. 2011; Reves et al. 2012). By loading antibiotics into two
individual parts of a composite scaffold, we hope to eliminate or minimize interactions
between the two therapeutic agents and to provide an extended elution profile for both
antibiotics.
In order to develop effective treatment of polymicrobial wounds, a co-delivery system
for two antibiotics from a bone graft substitute was fabricated from a composite of CaS
and C-nHA microspheres. Two antibiotics, amikacin and vancomycin, were used as
model therapeutic agents since they provide coverage over both Gram-positive
(vancomycin and amikacin) and Gram-negative (amikacin) pathogens. These antibiotics
were also selected as they are commonly used to treat infections such as MRSA and have
lower toxicity issues compared with other antibiotics (Edin et al. 1996; Zilberman and
Elsner 2008; Jackson et al. 2009; Atilla et al. 2010; Noel et al. 2010; Rathbone et al.
2011; Wenke and Guelcher 2011). While there is a potential for antagonistic, additive, or
synergistic interactions when co-delivering two antibiotics, no change in activity for
vancomycin or amikacin has been reported when co-delivered (Atilla et al. 2010; Noel et
al. 2010; Thomas et al. 2011; Sakamoto et al. 2013). Potential effects of the composite
scaffold on antibiotic activity will be examined. It is hypothesized that this composite
scaffold will be able to deliver antibiotics for an extended period of 4 weeks at
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biologically active levels and that the incorporation of C-nHA microspheres will aid in
extending the time course of elution of therapeutic agents.
2. Materials and Methods
2.1 Chitosan-HA Microsphere Fabrication
A previously described co-precipitation method was employed for the fabrication of
the composite chitosan-nano hydroxyapatite (C-nHA) microspheres (Chesnutt et al.
2009). Briefly, 3.57 g 80% DDA chitosan powder (260 kDa, Primex EHF, Siglufjordur,
Iceland) was dissolved in 84 mL of 2 wt% acetic acid and mixed with 10mL 1M CaCl2
and 6mL 1M NaH2PO4 (Ca:P ratio = 1.67). The mixture was slowly dripped into a
continuously stirred solution of 20% NaOH, 30% methanol, and 50% water (pH=13) to
precipitate spherical chitosan-calcium phosphate microspheres. The C-nHA microspheres
were kept in the precipitating solution for 24 hours to allow for the formation of nanocrystalline hydroxyapatite. The C-nHA microspheres were then washed with deionized
(DI) water until a neutral pH was achieved (pH 7-8). The C-nHA microspheres were
frozen at 20°C for one hour and then transferred to a 2.5 liter Labconco freeze-dryer for
48 hours to create lyophilized/porous C-nHA microspheres (Reves et al. 2009).
2.2 Composite Scaffold Fabrication and Antibiotic Loading
Each composite scaffold was made by mixing 600 mg of calcium sulfate (CaS, αhemihydrate, Wright Medical Technologies, Inc, Arlington, TN) and 80 mg lyophilized
C-nHA microspheres with 0.24mL of DI water. The mixture was pressed into a mold to
form a pellet that yielded a CaS to microsphere ratio of 88:12. This ratio was determined
empirically for the size of the beads and the amount of CaS that was necessary to hold the
scaffold together. C-nHA microspheres were pre-loaded via swelling (24 hrs at room
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temperature) with 1.5 mL amikacin (10 mg/mL, MP Biomedical, LLC. Solon, OH) in DI
water. Any remaining amikacin solution was removed and the C-nHA microspheres were
washed once with 3mL of dIH2O in order to remove non-absorbed drug. The C-nHA
microspheres were then mixed with CaS to form composite pellets. CaS was loaded with
0.24 mL vancomycin hydrochloride (75.2mg/mL, Acros Organics, New Jersey) in DI
water to yield 2 wt% of vancomycin per pellet. All pellets were dried overnight at room
temperature to allow conversion to dihydrate form of CaS before use. The handling
ability of the composite scaffold was tested after setting by manually pressing with a
spatula and observing any crushing or breaking of the pellets. Two control groups were
amikacin-loaded C-nHA microspheres (no CaS) and vancomycin-loaded CaS (no
microspheres). Five test groups were evaluated: (1) Amikacin loaded C-nHA
Microspheres incorporated into Vancomycin loaded Calcium sulfate (AMVC), (2)
Amikacin C-nHA Microspheres alone (AM, control), (3) Vancomycin loaded Calcium
sulfate without microspheres (VC, control), (4) Amikacin C-nHA Microspheres in
Calcium sulfate without vancomycin (AMC) and (5) C-nHA Microspheres without
amikacin in Vancomycin loaded Calcium sulfate (MVC). Vancomycin is commonly
loaded in CaS and thus we loaded it into the CaS matrix components of our scaffold
(Wichelhaus et al. 2001; Gitelis and Brebach 2002; Rauschmann et al. 2005; Jackson et
al. 2009; Atilla et al. 2010; McPherson et al. 2013). We choose amikacin because it is
effective against many types of bacteria such as Acinetobacter, Pseudomonas, and
Enterobacter (Petersen et al. 2007). The C-nHA microspheres were loaded with amikacin
and incorporated into calcium sulfate in order to prolong the antibiotic release.
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2.3 Antibiotic Elution and Degradation
Specimens (n=5 per group) were placed in individual wells of 48-well plates with 1.5
mL PBS. Elution samples were taken at 1, 5, 12, 24 hrs and 2, 4, 7, 14, 20, 27, 34 and 42
days. The PBS solution was completely refreshed after each elution time point. The
collected elution samples were analyzed with a fluorescent polarization immunoassay
(TDxFLx; Abbott Laboratories, Abbott Park, IL) (Jackson et al. 2009; Noel et al. 2010;
Doty et al. 2014). Percent degradation and antibiotic release were calculated with Eqs. (1)
and Eqs. (2) respectively.

% !"#$%&%'()* =

!"#$#%& !"##!!"#$% !"##
!"#$#%& !"##

% !"#$%$&#$' !"#$%"&' = 100 −

!! !!!
!!

∗ 100

∗ 100

(1)

(2)

Where AL = Theoretical amount of loaded antibiotic and AC = Cumulative antibiotic
release over 42 days. The theoretical amount of amikacin was determined by dissolving
three sets of amikacin-loaded C-nHA microspheres (as mentioned above for scaffold
fabrication) in 5mL of 1% acetic acid overnight. The dissolved solution was frozen at 20C until analysis. The theoretical amount of vancomycin was calculated by the amount
that was loaded into each scaffold.
2.4 Inhibition of Growth and Bactericidal Assay
Turbidity assays using S. aureus (Cowan I strain, ATCC 12598, Manassas, VA) and
P. aeruginosa (ATCC 27317, Manassas, VA) in trypticase soy broth (TSB) were used to
evaluate the inhibitory effectiveness of the released antibiotics (Noel et al. 2010; Doty et
al. 2014). Techniques were adapted from the Clinical and Laboratory Standard Method
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M07-A9 (CLSI 2012). Briefly, 200 µl composite scaffold eluates were added to sterile
tubes containing 1.75 ml Trypticase soy broth (TSB) and inoculated with ~2x106 colony
forming units (CFU) of S. aureus and P. aeruginosa respectively. Turbidity was
determined spectrophotometrically (Spectronic Instruments, 20 Genesis) at OD530 after an
overnight incubation at 37 °C and no-growth was indicated by OD <0.050. Bactericidal
activity of samples was determined by plating dilutions of all samples that inhibited
growth. Those samples that killed greater than 99.9% of the inoculum were considered
bactericidal.
2.5 Statistical Analysis
Statistical analysis was performed with a Two-Way ANOVA on the release of
vancomycin and amikacin from the composite scaffolds and on the activity of the eluates
between groups and over time. Composite scaffold degradation was analyzed with OneWay ANOVA. Post hoc analysis was carried out with Student-Newman-Keuls (SNK,
P<0.05) when statistical differences were present. Turbidity and bactericidal statistical
analysis performed with proportions test using contingency tables between the rate of
inhibition of growth or bactericidal effect with a Fisher Exact test.
3. Results
3.1 Chitosan-nHA Microsphere Fabrication
Chitosan-nHA microspheres were teardrop shaped, with a textured surface and a
diameter of 1.40mm ± 0.23mm (Fig. 1). The composite scaffold measured approximately
12.5mm diameter by 6.5mm high, with C-nHA microspheres uniformly distributed
throughout. The set pellet was hard and did not crumble with manipulation of forceps.
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Fig. 1 Digital microscopy images (Keyence VHX-1000) of calcium sulfate powder
(A), lyophilized chitosan-nHA microspheres (B), and composite pellet of chitosannHA microspheres incorporated into calcium sulfate (C).

3.2 Composite Scaffold Elution and Degradation
Elution data showed that amikacin loaded C-nHA microspheres embedded in CaS
with or without vancomycin (AMC and AMVC) exhibited a reduced burst and extended
the release of amikacin compared to elution from C-nHA microspheres (AM) alone
(P<0.001) (Fig 2). Statistical analyses indicated a significant interaction between time
and groups (p< 0.001). Because of this interaction, subsequent analysis evaluated groups
at each time point. There were statistically significant differences in the release of
amikacin from AM, AMVC and AMC at every time point (p<0.05 except at 5hr,
p=0.132). Amikacin release from AM was significantly greater than either AMC or
AMVC (p<0.05) only at the 1hr time point. After 5hrs, the amikacin release from AM
was significantly less than AMC and AMVC at every time point (p<0.05). This indicated
a very rapid burst release from the C-nHA microspheres alone (AM) as compared to
microspheres incorporated into the CaS matrix (AMVC/AMC). Initially, at 1hr, the
amikacin release from AMC was higher than that of AMVC, but by 5hr there were no
differences. From 12hr to14 days the AMVC released more amikacin than AMC but at
Day 20 this shifted and AMC released more than AMVC throughout the rest of the study.
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Amikacin recovery for all groups, regardless of the elution profile, was 41-42% and there
were no statistical differences in percent recovery between the three groups, p = 0.582
(Table 1).

Fig. 2 Amikacin elution from scaffolds composed of chitosan-nHA microspheres
embedded in calcium sulfate with or without vancomycin (AMC and AMVC) and
amikacin loaded chitosan-nHA microspheres (AM) over 42 days. (#) Indicates no
statistical difference.

The vancomycin release profile for all three groups showed an initial burst and
subsequent decay over time (Fig. 3). Significant differences in the vancomycin release
over time (p<0.05) were detected as well as significant interactions between time and
group factors (p<0.05) indicating that the release of vancomycin was dependent on both
time and scaffold composition. Further analysis at each time point revealed that there
were statistical differences in vancomycin release between groups at all time points
(p<0.05) except for 1hr where no statistical differences were reported (p=0.053). The
vancomycin release from VC was notably high through day 2, and then dropped rapidly
20

exhibiting the statistically lowest levels of release for the rest of the study. Vancomycin
release from MVC remained high through day 4, and then, similar to the VC, exhibited a
drop in release, but the drop was less dramatic, and the levels of release remained
statistically higher than VC after day 4. AMVC followed a different release pattern, with
a statistically lower release compared to the other groups from 12hr through day 2 and a
statistically higher release from day 4 to 42 suggesting a reduction in initial burst with a
concomitant extension of vancomycin release. Vancomycin recovery from the scaffolds
was nearly complete at 98-102%, with no statistical differences, p=0.133 (Table 1).

Fig. 3 Vancomycin elution from scaffolds composed of chitosan-nHA microspheres
embedded in calcium sulfate with or without amikacin (MVC and AMVC) and
vancomycin loaded calcium sulfate (VC) over 42 days. (#) Indicates no statistical
difference.

Pellets exhibited an average change in mass of 47 ± 3% after six weeks and no
statistical differences were noted, p= 0.064 (Table 1).
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Table 1 Antibiotic recovery and change in mass of composite scaffolds over 6 weeks
(n=5).
% Amikacin % Vancomycin
Group
% Degradation
Recovery
Recovery
AMVC 41.35 ± 1.91 102.42 ± 2.33
47.8 ± 2.3
VC
na
102.00 ± 1.44
46.5 ± 1.5
AMC 41.04 ± 1.50
na
47.1 ± 3.4
MVC
na
98.72 ± 4.20
45.1 ± 3.5
AM
42.45 ± 2.94
na
nd
na – not applicable because drug not in scaffold. nd – not determined, degradation was
determined for composite scaffold only.

3.3 Inhibition of Growth and Bactericidal Assay
The turbidity assays showed that the antibiotics eluted from AMVC inhibited S.
aureus growth for 34 days and was bactericidal for 27days (Table 2). Groups VC and
MVC were effective in inhibiting and killing S. aureus for 14 and 27 days respectively.
Group AMVC abated P. aeruginosa for 24 hrs but was bactericidal for only 1 hr. Groups
AM and AMC showed inhibition of P. aeruginosa through 24hrs and bacterial killing for
5 hrs.
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Table 2 Bacteriostatic and bactericidal activity of eluates containing vancomycin against
S. aureus, and amikacin against P. aeruginosa (n=5). (-) indicates no growth, (+)
indicates growth, (--) indicates reduction in the number of surviving CFU from the
inoculum by 99.9% (killing), (++) indicates CFU growth > 0.01% of inoculum (no
killing) and (--/++) partial killing in replicate samples due to slight variations in drug
release at levels near the MIC. Symbol (*) denotes a statistical difference in proportion
between (- or --) inhibitory group(s) and (+ or ++) non-inhibitory group(s) at a given time
point (p<0.05).
S. aureus
Bacteriostatic

P. aeruginosa

Bactericidal

Bacteriostatic

VC MVC AMVC VC MVC AMVC AM AMC AMVC

1hr
5hr
12hr
24hr
2d
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4. Discussion
In this study we evaluated in vitro a composite bone graft substitute for the dual
delivery of vancomycin and amikacin to address the problem of treating polymicrobial
orthopedic infections. Amikacin was absorbed into the C-nHA microspheres (36mg/g
microsphere), and combined with the vancomycin-loaded CaS component (2wt% of CaS)
without affecting the handling properties of the scaffold after setting, unlike some studies
that report changes in crushability and setability with quinolone antibiotics or daptomycin
(Mousset et al. 1995; Richelsoph et al. 2007). These two antibiotics were used to create a
broad-spectrum antibiotic effect against both P. aeruginosa, and S. aureus, two bacteria
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commonly found in orthopaedic wounds (Hatzenbuehler and Pulling 2011; Hogan et al.
2013). This study demonstrates that the use of the C-nHA microspheres and dualantibiotic loading reduced the in vitro burst release and extended the elution of both
antibiotics compared to CaS or C-nHA microspheres alone. All scaffolds, regardless of
composition, were less effective in inhibiting and killing P. aeruginosa than S. aureus. In
bone scaffolds that incorporated C-nHA microspheres and vancomycin, the bacterial
inhibition and killing of S. aureus was improved by 50-60% as compared to the
vancomycin-loaded calcium sulfate group. In the presence of both antibiotics, the
inhibition of S. aureus was further extended 20% due to an extended release and positive
interaction between amikacin and vancomycin (Gentry 1997). The most effective
antibacterial results reported for S. aureus were expected because the elution values of
vancomycin containing scaffolds were 100-1000x above the breakpoint MIC (1µg/mL)
for S. aureus for 7 days, whereas the highest elution value for amikacin was 55-130x
above the breakpoint MIC (4µg/mL) for P. aeruginosa at 1hr (Jackson et al. 2009; Noel
et al. 2010).
Even though the vancomycin release for AMC was lower in the initial time points than
the other groups, there was an extended elution that allowed the composite to remain
active against S. aureus for the greatest amount of time and within the recommended 4-6
weeks period for antibiotic treatment of orthopaedic wounds (Lew and Waldvogel 1997;
Lazzarini et al. 2004; Nair et al. 2011). After 7 days, 96% of vancomycin was recovered
from eluates for the AMVC and VCM composites compared to the same recovery after
only 2 days for VC scaffolds, which shows the significant elution extension in the
presence of C-nHA microspheres. One possible mechanism for the extended release is
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that vancomycin was absorbed into and retained by the exterior surface of the porous CnHA microspheres during preparation. The large vancomycin molecules could have
become entangled in the C-nHA microspheres and further delayed the antibiotic release.
The bacterial inhibition we report for our dual-loaded scaffold containing C-nHA
microspheres is 33 days longer than the 18-24 hour inhibition against several types of S.
aureus (including MRSA) and S. intermedius reported by Atilla et al. for dual-loaded
amikacin and vancomycin CaS beads (Atilla et al. 2010). Additionally, Howlin et al.
reported no benefit in dual-loaded vancomycin-tobramycin CaS beads over single-loaded
vancomycin CaS beads in zone of inhibition (ZOI) tests against MRSA (Howlin et al.
2015). Even though vancomycin recovery from the dual-loaded scaffold at day 34 was
102 ± 2%, there remained high enough concentration to inhibit S. aureus at this time
point. This indicates that the CaS and C-nHA microspheres did not affect the activity of
eluted antibiotics. The high recovery of vancomycin for all groups not only contributes to
the extended antibiotic activity but also leads to less risk of bacterial resistance from
long-term low-level elution.
The amikacin release also followed a burst release pattern similar to other studies that
report drug release from chitosan microspheres (Sinha et al. 2004; Aranaz et al. 2009;
Reves et al. 2009). The delayed burst effect from groups containing C-nHA embedded in
CaS, may be due to the physical barrier of calcium sulfate slowing elution or possible
interactions with the matrix. Therefore, it is understandable that the amikacin recovery
from AM is ~40% at 2 days compared to groups with C-nHA microspheres, where the
recovery is ~40% after 14 days. A similar elution delay was noted in Doty et al. where a
CaS matrix acted as a physical barrier and caused a one-day delay in rhBMP-2 elution
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(Doty et al. 2014). While the amikacin elution fell below the MIC on days 7 and 27 for
groups AM and AMVC respectively, the release for AMC was detectable throughout the
42-day time course, suggesting that amikacin was still entrapped within the matrix and
being slowly released. Although the eluted amikacin concentrations were 3-17 fold
higher than MIC levels at 24hrs, the reduced efficacy of bacterial inhibition and killing
compared to the measured concentrations may indicate that the drug is reacting with
matrix components and either being inactivated or possibly forming a salt. Atilla et al.
reported possible inactivation of amikacin when in lower pH environment, as may occur
at the micro level with degrading CaS (Walsh et al. 2003; Atilla et al. 2010). Thus, the
amikacin activity in the composite scaffolds may have been compromised and the activity
reduced. Overall, our amikacin release was extended 2.6-4 times longer than what Atilla
et al. reported for a dual amikacin-vancomycin-loaded plain CaS scaffold, indicating a
benefit of slowed and extended release using C-nHA microspheres with CaS matrix
(Atilla et al. 2010). Although Atilla et al. tested different strains of bacteria; they also
reported short antimicrobial activity times of eluates, 18-24hr for scaffolds containing
both antibiotics, possibly due to amikacin inactivation in a CaS environment (Atilla et al.
2010). Future studies would require investigation into increasing the amikacin
concentration, improving the loading efficiency and/or choosing another non-pH affected
antibiotic in order to achieve a longer bacterial inhibition period.
A look into the antibiotic loading of CaS and C-nHA microspheres reveals information
about the elution potential. Vancomycin was loaded at 2 wt%, which is an effective “low
dose” for premixed cements (Clyburn and Cui 2007). Although we achieved ~5 times
higher amikacin loading than Reves et al. (~6.5mg/g chitosan) (Reves et al. 2009) our
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amikacin loading yielded only 0.42 wt% pellet (36.7 mg/g chitosan), a much smaller
amount compared to the vancomycin loading. Thus, it is understandable that the
vancomycin eluates were able to sustain a longer activity against bacteria in vitro than the
amikacin eluates. Inefficient loading, loss of amikacin upon loading (washing step), or
inactivation could explain why the amikacin recovery was only ~41%. It is possible that
increasing the surface area of the microsphere would allow more antibiotic absorption,
thus using chitosan nanoparticles instead of microspheres could result in higher loading
and subsequent release (Masri et al. 1995; Phillips et al. 2007; Romainor et al. 2014). The
overall benefit of C-nHA microspheres in the CaS matrix loaded with two antibiotics is a
slowed initial and extended elution rate for amikacin, despite the low antibiotic levels and
the possible inactivation of amikacin in CaS. It is likely that by increasing antibiotic
loading levels in the C-nHA microspheres or by using an alternative antibiotic to
amikacin, the issues of reduced activity and short duration of elution could be minimized.
This preliminary work is limited to in vitro assays and offers no direct correlation to
clinical efficacy. However, it does provide valuable foundational information about the
co-delivery of two antibiotics from a CaS based scaffold that can be used to further
develop composite implant strategies. The antibacterial assays for vancomycin suggest
that extended elution would occur in vivo. The interactions of antibiotics with bone
scaffold materials is not well known, and although in this study a composite approach
altered elution and antibiotic activity, the exact mechanisms by which these effects
occurred is not well understood. Further work is needed to improve the efficiency of
amikacin loading and elution to determine if residual drug is remaining in the scaffold.
Evaluating the effects of combinations of antibiotics and calcium sulfate in solution as
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well as antibiotic salts may help to determine reasons for the lack of antibiotic activity
against microorganisms at inhibitory concentrations. Additionally, more pH stable
antibiotics may be studied to replace amikacin in the C-nHA microspheres, or synthetic
calcium sulfates could be used as they have less acidic degradation products as well as
extended elution (Parker et al. 2011; McPherson et al. 2013). A long-range goal, not
encompassed in this work, would be for the slower-degrading, C-nHA microspheres to
provide an osteoconductive scaffold for tissue regeneration as the CaS is resorbed.
5. Conclusion
Our goal to deliver therapeutically active antibiotics for 4 weeks from our composite
scaffold was exceeded for the vancomycin release only, with the composite scaffold
containing both amikacin and vancomycin. The dual antibiotic loaded calcium sulfatechitosan-nHA microsphere composite scaffold was able to elute and sustain bacterial
activity against S. aureus for 2.4 times longer than vancomycin loaded calcium sulfate
scaffolds alone. The amikacin loaded into the chitosan-nHA microspheres did show a
slightly extended elution when embedded in the calcium sulfate matrix compared to free
chitosan-nHA microspheres, however, the amikacin may have been inactivated in the
calcium sulfate scaffold as it was degrading. Together these results indicate that dual
antibiotic delivery over an extended period in one scaffold is possible and favorable
compared to single antibiotic delivery systems. Loading one antibiotic into each
component of the scaffold helped to slow the elution of both agents. Modifications to
improve elution of amikacin could make this dual delivery method advantageous for
treatment of orthopaedic wounds with polymicrobial infection. Studies evaluating these
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biomaterials in preclinical models of contaminated musculoskeletal trauma should follow
to confirm potential clinical efficacy.
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CHAPTER 3
COMPOSITE CHITOSAN AND CALCIUM SULFATE SCAFFOLD FOR DUAL
DELIVERY OF VANCOMYCIN AND RECOMBINANT HUMAN BONE
MORPHOGENETIC PROTEIN-2

Introduction
Worldwide, two million people require bone-grafting procedures every year to repair
injuries from traumatic events or disease [1]. In the US alone, approximately 112,000
device related infections occur every year [2]. Additionally, conflicts in Iraq and
Afghanistan have led to more than 21,000 combat injuries, of which approximately 65%
are orthopaedic related traumas [3]. Combat wounds are largely extremity injuries, with
23-39% being fractures, the majority of which are open wounds [4,5]. The incidents of
infection in open fractures from civilian or combat cases averages around 10-20% but can
be as low or high as 0-60% depending on the location and type of fracture, typically
increasing with wound severity [2,5–7]. Infections in these complex musculoskeletal
injuries can lead to non-unions, multiple surgical procedures, loss of function, prolonged
recovery times, causing a greater burden on the healthcare system [5,8]. A leading cause
of nosocomial infections, Staphylococcus aureus (S. aureus), is one of many bacteria that
pose a severe threat to wound healing especially when drug resistance is acquired [9,10].
Uncontrolled, such bacterial contaminations can lead to limb amputation and patient
death [11,12]. Thus, there is an important need for a multi-functioning bone graft capable
of delivering pharmaceutical agents to prevent infection, simulate healing, and provide a
substrate for bone regeneration.
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In traumatic fractures, the natural immune response and effectiveness of systemic
antibiotics can be significantly reduced when the vasculature is severely compromised
[13,14]. To combat this, high levels of systemic antibiotics are used so that therapeutic
levels can reach the wound site, however, this can cause organ toxicity and antibiotic
resistance [13,14]. The local delivery of antibiotics is an alternative strategy that has been
proven to be effective in delivering therapeutic doses of antibiotics to infected wound
sites without toxicity issues [8,15,16]. Polymethylmethacrylate (PMMA) is the gold
standard for local antibiotic delivery in infected wounds, however, it is not degradable,
requires a second surgery for removal and can release subtherapeutic levels of antibiotics
that may lead to bacterial resistance and/or reinfection [2,8,13,17]. Biodegradable local
delivery systems, such as calcium sulfate, also overcome the challenges of systemic
delivery in wounds with compromised vasculature and do not require a second surgery
for removal or have the associated bacterial resistance potential since they dissolve in
vivo [2,14,17,18].
Successful healing of large fractures also requires concurrent tissue and bone
regeneration in addition to infection control [2,6]. Treatments that address infection and
tissue regeneration typically include a growth factor such as rhBMP-2 and an antibiotic,
such as gentamicin, vancomycin or tobramycin. In vitro studies investigating dual
delivery of antibiotics and rhBMP-2 from a titanium substrate or degradable polymers
demonstrated that alkaline phosphatases (ALP) production by bone cells was greater
when exposed to eluates containing both antibiotic and rhBMP-2 as compared to just
antibiotics [19–21]. These studies showed unique delivery methods for dual therapeutic
agents, but could not be customized in the operating room since their materials are
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prepared in advance [19–21]. Delivery systems that can be customized are advantageous
because the physician can tailor the therapeutic agents for individual needs and more
effectively treat the patient [9,22]. Additionally, very few dual delivery studies for the
treatment of infected bone fractures have examined the therapeutic interactions of eluted
agents. Glatt et al. and Strobel et al. showed that the dual delivery of rhBMP-2 and high
levels of antibiotics (600-1000 µg/mL Tobramycin and 10% wt gentamicin respectively)
reduce the ALP production of cells compared to controls and cells exposed to lower
concentrations of antibiotic [23,24]. These studies show that interactions of dual
delivered agents can reduce the overall efficacy of the system. Thus, in order to develop a
clinically relevant bone graft that can be customized to the patient, research and selection
of appropriate therapeutic agents must be investigated.
The effectiveness of delivering both rhBMP-2 and an antibiotic has been evaluated
in a rat model with a collagen sponge [23] and degradable block copolymer [8], calcium
sulfate scaffolds [25] and polyurethane scaffolds [26]. Glatt et al. and Suzuki et al.
showed significant bone healing in the presence of scaffolds loaded with rhBMP-2 and
antibiotic compared to scaffolds with no therapeutic agents, however, the inability to
maintain 3D space [23] and manufacturing pre-loaded scaffolds [8] limit the use of these
scaffolds. Similarly, Wang et al. found that in vitro and in vivo cellular response to
calcium sulfate scaffolds containing rhBMP-2 and vancomycin showed significant
increases over scaffolds containing no factors or vancomycin alone [25]. However,
supraphysiological doses of rhBMP-2, as used by Wang et al. still cause concern for
researchers and physicians alike [27,28]. In the presence of infection, Guelcher et al.
showed that scaffolds loaded with rhBMP-2 (2.5 µg) and vancomycin (340 µg)
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significantly increased the amount of regenerated bone compared to scaffolds with
rhBMP-2 only. Scaffolds loaded with supraphysiological levels (25 µg) of rhBMP-2 were
able to regenerate bone regardless of vancomycin delivery [26]. While this study showed
that dual delivery was able to reduce the need for higher growth factor dosing, Guelcher
et al. also reported inconsistent scaffold degradation with some scaffolds inhibiting
cellular ingrowth, a problem that would affect short and long term healing. Nevertheless,
these studies demonstrate that the co-delivery of rhBMP-2 and certain antibiotics is
possible and effective in regenerating bone compared to controls. However, the
shortcomings of these systems continue to be a lack of information about the interactions
of co-delivered agents, systems that are not customizable by the surgeon in the operating
room, and the use of supraphysiological doses of growth factor to compensate for burst
release kinetics and enzymatic degradation [23,29].
The aim of this study is to develop a degradable composite for the treatment of large,
infected bone injuries based on: chitosan microspheres for delivery of rhBMP-2 and
calcium sulfate (CS) bone cement for delivery of an antibiotic, vancomycin. Vancomycin
is commonly used antibiotic for the treatment of Gram-positive bacteria including
methicillin-resistant Staphylococcus aureus (MRSA). Chitosan microspheres were
selected because they are biodegradable, biocompatible and show promise as a
drug/growth factor delivery vehicle [30–33]. Surgical-grade CS is a FDA approved bone
graft material, has a predictable and rapid (~2 months) resorption rate and encourages
angiogenesis and osteogenesis as it dissolves [34,35]. In addition CS cements have been
used as a treatment for osteomyelitis since they sustain the release of antibiotics for
several weeks [8,36]. In our approach, the microspheres loaded with rhBMP-2 (at low
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concentrations) will be embedded in CS. The CS will act as a physical barrier to delay,
slow and prolong growth factor release from embedded microspheres. The CS will act as
a substrate to support bone healing and at the same time it will serve as a local delivery
vehicle for vancomycin to treat/prevent infections in a wound site. The goals of this study
are to develop a composite system that will be easily sterilizable, affordable, and able to
be prepared in the operating room and can release antibiotics for 2-4 weeks for the
prevention/elimination of bacterial infections as well as provide a delayed but sustained
release of BMP. In this study we will evaluate the set time, drug release profiles,
antimicrobial and cytocompatible properties of the composite graft as well as the in vitro
effect of vancomycin on rhBMP-2 activity.
Materials and Methods
Chitosan-Calcium Phosphate Microsphere Fabrication
A co-precipitation method as previously described was used for the fabrication of the
chitosan/calcium phosphate composite microspheres [32]. Briefly a 3.57 wt% chitosan
(80% DDA, 260 kDa, Primex EHF, Siglufjordur, Iceland) in 2 wt% acetic acid solution
containing 0.1 M CaCl2, 0.1 M NaH2PO4, was dripped into a 20% NaOH, 30% methanol,
50% deionized (dI) water (pH=13) solution to precipitate spherical microspheres. After
24 hours in precipitating base solution to form crystalline hydroxyapatite, the
microspheres were washed with dIH2O to pH 7-8, frozen for 2 hours at -80oC and
lyophilized (Labconco FreeZone 2.5). The final microspheres were sterilized with
ethylene oxide gas.
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Pharmaceutical Loading and Composite Scaffold Fabrication
The composite scaffold was comprised of 100 mg microspheres and 0.6g CS
(Calcium Sulfate, α-hemihydrate, Wright Medical Technologies, Inc, Arlington, TN).
Prior to combining the two components, the microspheres were loaded with either 33.3
µg /mL rhBMP-2 (PeproTech, Rocky Hill, NJ) or 6.66 mg/mL vancomycin
hydrochloride (MP Biomedical, Solon, OH) at room temperature (RT) for 15 minutes
(Table 1). The composite graft was made by mixing 0.6 g CS and 180 µL vancomycin
[86.7mg/mL] in a 13mm diameter x 7mm high polyethylene mold with microspheres and
thoroughly mixed for 40 stirs in 20 seconds. The mold was tapped 20 times on the bench
to remove air bubbles and allowed to set.

Table 1: Key to composites and relative loading of vancomycin and rhBMP-2.
Nomenclature: CS2/CS0, represents the wt% of vancomycin in the CS component and
symbols in parentheses represent the mass ratio of B (rhBMP-2) or V (vancomycin)
loaded into the microspheres.

Group

CS2(B0V4)
CS2(B4V0)
CS2(B1V3)
CS2(B2V2)
CS2(B3V1)
CS2(B0V0)*
CS0(B0V0)*

Vancomycin
in the CS (mg)
(2% wt
vancomycin)
15.6
15.6
15.6
15.6
15.6
15.6
0

Relative mass
ratio of rhBMP2 containing
microspheres to
vancomycin
containing
microspheres
within CS
0:4
4:0
1:3
2:2
3:1
---

rhBMP-2 (µg) in
composite
microspheres
based on relative
ratio of
microspheres
(46±8µg rhBMP2/g microsphere)
0
5
1.25
2.5
3.75
0
0

Vancomycin (mg) in
composite
microspheres based
on relative ratio of
microspheres (mg)
(9.3±2.2mg
vancomycin/g
microsphere)
1
0
0.75
0.5
0.25
0
0

* controls, deionized water was used in place of vancomycin or rhBMP-2.
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Viacat hardness test
To determine if the addition of microspheres and pharmaceutical agents affected
the set time of the material, a set test based on the ASTM Standard C472.26 (Standard
Test Methods for Physical Testing of Gypsum, Gypsum Plasters and Gypsum Concrete,
ASTM, Inc., PA, USA), was performed. The Viacat needle (1mm diameter) was allowed
to penetrate the sample and the height was recorded. The test was repeated until the
needle penetrated less than half the original height, at which time the material was
considered set. Only the groups with the highest concentrations of therapeutic agents
were tested against control scaffolds containing no therapeutic agents (CS2(B0V4),
CS2(B4V0), CS2(B0V0), and CS0(B0V0), n=3) since the set time will be influenced
most at the highest drug concentrations.
Composite Scaffold Elution and Degradation
To evaluate the release of rhBMP-2 and vancomycin, scaffolds (n=5/group) were
placed in 3 mL of McCoy’s 5A medium +10% Fetal Bovine Serum (FBS) and placed in
an incubator at 37oC. At 1, 2, 3, 5, 7, 9, 11, 14, 18, 21, 28, 35 and 42 days, the medium
was completely removed, replaced with fresh medium and returned to the incubator.
Eluates were stored at -20oC until analyzed. rhBMP-2 and vancomycin release were
measured with an Enzyme-Linked Immunosorbent Assay (ELISA) (PeproTech, Rocky
Hill, NJ) and Fluorescence Polarization Immunoassay (FPIA) (TDxFLx, Abbott
Laboratories) respectively. For the degradation study of the composite scaffolds, mass
was recorded prior to and post elution.
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Bacteriostatic and Bactericidal Assay Analysis
To test antibacterial activity of released vancomycin, a method adapted from the
Clinical and Laboratory Standard Method M07-A9 was performed [37]. Briefly, tubes
containing 1.75 mL of trypticase soy broth were inoculated with 50 µL of 2x106 colony
forming units (CFU) of S. aureus (Cowan I strain, ATCC 12598, Manassas, VA), and
200 µL of composite scaffold eluates. After incubating overnight at 37oC, the turbidity
was determined spectrophotometrically (Spectronic Instruments, 20 Genesis) at OD530,
and no-growth was indicated by OD <0.050. To determine if the released vancomycin
was not only bacteriostatic but also bactericidal, the samples that exhibited no bacterial
growth were plated (50 µL) onto TSB plates and incubated overnight at 37oC and viable
CFU were counted on the plates. Eluates were considered bactericidal if there was a
99.9% reduction in CFU of the inoculum.
Determination of rhBMP-2 Activity in Eluates
W-20-17 cells (ATCC CRL-2623, Manassas, VA) were seeded at 3x104cells/cm2
with DMEM High Glucose in 96 well plates for 24 hours at 37oC and 5% CO2. Cells
were washed three times with 200 µL PBS and then exposed to 200 µL of the collected
eluates for 24 hours at 37oC and 5% CO2. Viability was determined with CellTiter
Aqueous One Solution Cell Proliferation Assay (Promega, Madison, WI) and rhBMP-2
activity was determined with an alkaline phosphatase (ALP) assay. ALP assay was
conducted by lysing cells in 80 µL RNA free H2O with two freeze thaws at -80oC,
followed by the addition of 20 µL 0.5M alkaline buffer (Sigma-Aldrich, St. Louis, MO),
100 µL 5mM Phosphatase substrate (Sigma-Aldrich, St. Louis, MO) and 50 minutes
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incubation at 37oC. 100 µL of 0.3M NaOH stop solution was then added and the plate
was read spectrophotometrically (Molecular Devices, SpectraMAX Plus) at 405nm.
Detection of rhBMP-2 Elution from Microspheres
To help determine the role of CS as a barrier for rhBMP-2 release, the elution of
rhBMP-2 was evaluated from microspheres alone. Microspheres (100 mg) were loaded as
previously described with 5 µg rhBMP-2 and eluted for 6 weeks in 3 mL of McCoy’s 5A
+ 1% Bovine Serum Albumin (BSA) to reduce non-specific adsorption of rhBMP-2.
Additionally, to check the effects of sampling intervals, two groups of microspheres were
tested; eluates were collected daily for six weeks in one group and eluates were collected
at intervals to match those used in the six-week elution test of composites for the second
group. Eluates were completely refreshed at every collection and stored at -20oC until
analysis.
Determination of rhBMP-2 Activity in the Presence of Vancomycin
To investigate the possible interactions of rhBMP-2 and vancomycin without any
interference from the calcium sulfate matrix, W20-17 cells were used to perform an in
vitro assessment. Cells were exposed to 200 µL of a dual agent solution made in DMEM
High Glucose Medium of rhBMP-2 (0,10,50,100,500,1000 ng/mL) and vancomycin (0,
12.5, 450, 1800, 3600 µg/mL). After 24 hours, cellular viability and activity were
determined spectrophotometrically.
Statistical Analysis
Statistical analysis was performed with a Two-Way ANOVA on the release of
vancomycin and rhBMP-2 from the composite scaffolds over time and on the activity of
the eluates and dual agent solutions in culture. Composite scaffold setting time and

42

degradation was analyzed with One-Way ANOVA. When statistical differences were
detected, post hoc analysis was carried out with Student –Newman-Keuls (SNK, P<0.05).
Results
Chitosan-Calcium Phosphate Microsphere –Calcium Sulfate Composite Scaffold
Fabrication
Chitosan-calcium phosphate microspheres were precipitated and lyophilized (Fig.
1a). Average size of the microspheres was 1.40mm ± 0.23mm, the shape was teardrop
and the surface had a textured appearance (Fig. 1a). Composite scaffolds had uniformly
distributed microspheres and maintained their shape after removal from the mold (Fig.
1c). The pellet was firm and did not crumble when manipulated with forceps.

Fig. 1 Lyophilized chitosan-calcium phosphate microspheres (a), calcium sulfate powder
(b), and composite pellet of microspheres incorporated into calcium sulfate(c), close up
of lyophilized chitosan-calcium phosphate microspheres (scale bar 2000 µm)

Viacat Hardness Test
The Viacat test demonstrated cement set times between 18-36 minutes for the groups
tested. The composite with rhBMP-2 loaded microspheres took statistically longer to set
than the other groups, however, all were set under 36 minutes (p<0.05) (Table 2).
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Table 2: Composite scaffold set times in minutes ± mean standard deviation (std).
Symbols (*) indicate statistical difference from symbol (#) at p<0.05.
Group
CS0
CS2
CS2(B0V0) CS2(B0V4) CS2(B4V0)
#
#
Time 19.68 ± 1.51 20.63 ± 1.62 31.94 ± 0.48* 20.50 ± 1.46# 33.85 ± 1.54*

Composite Scaffold Elution
The release profile of vancomycin from composite scaffolds showed a burst release
over the first two days followed by continuous low-level release (Fig. 2). The percent of
vancomycin recovered from the scaffolds was 99.32 ± 2.37%. Statistical differences were
found over time (p< 0.001) and between groups (p< 0.007) and there was a significant
interaction between time and groups (p< 0.001), indicating that the release is dependent
not only on time but also on the composition of the scaffold. Subsequent analysis
evaluated groups at each time points and post hoc analyses revealed that there were
statistical differences in vancomycin release between some groups on days 1, 2 and 3.
However, differences were not consistent between groups over these three measurement
periods (data not shown) and are most likely due to slight variations in the composition of
the hand made samples. After day 3 no statistical differences were observed within a time
point for vancomycin release from any of the groups. Overtime, the vancomycin
exhibited a burst release with the highest levels being released on day 1 and decreasing
over time. By day 18, there was no statistical difference in vancomycin release over the
end time points.

44

Fig. 2 Vancomycin elution from composite scaffold (n=5). Groups with similar symbols
(&, #, %, +) indicate no statistical difference between days at p>0.05.

The results of the analysis of rhBMP-2 release from the composite scaffolds are
shown in Fig. 3. Significant differences in rhBMP-2 released over time and between
groups (p<0.001) were detected as well as significant interactions between time and
group factors (p<0.001) which indicates that the release is depended on time and graft
composition. The scaffolds showed a dose dependent release for the scaffolds loaded
with the greatest amount of rhBMP-2 (CS2(B4V0); 5 µg rhBMP-2/pellet) showing the
greatest release at all time points followed by each group in order of amount of rhBMP-2
loading. Despite the interactions, a clear trend can be seen in the data of a delayed and
continuous release over the 42 days study.
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Fig. 3 rhBMP-2 Elution from composite scaffolds (n=5)

The composite scaffolds lost approximately 40% mass over six weeks (Table 3),
with statistical differences between groups CS0(B0V0), CS2(B2V2) and CS2(B3V1)
(p=0.014 and p=0.029 respectively).

Table 3: Recovery and change in mass of composite scaffolds over 6 weeks (n=5).
Symbols (*) indicate statistical difference from symbol (#) at p<0.05.
Group
CS2(B0V4)
CS2(B4V0)
CS2(B3V1)
CS2(B2V2)
CS2(B1V3)
CS2(B0V0)
CS0(B0V0)

%
rhBMP-2
Recovery
na
1.17
1.07
1.0
0.98
na
na

%
Vancomycin
Recovery
102.18
96.19
98.96
101.75
97.27
99.61
na

Average
Starting Mass
(g) ± std
0.950 ± 0.010
0.933 ± 0.017
0.938 ± 0.016#
0.920 ± 0.021*
0.925 ± 0.018
0.942 ± 0.021
0.920 ± 0.014*

Average
Ending Mass
(g) ± std
0.567 ± 0.014
0.560 ± 0.013
0.553 ± 0.021
0.564 ± 0.011
0.564 ± 0.008
0.564 ± 0.005
0.567 ± 0.007

%
Decrease
40.2 ± 0.01
40.0 ± 0.02
41.1 ± 0.03
38.7 ± 0.01
39.0 ± 0.01
40.1 ± 0.01
38.3 ± 0.01

Elution of released rhBMP-2 from chitosan microspheres
Cumulative release of rhBMP-2 from chitosan microspheres sampled every day was
240.98 ± 14.34 ng/mL (20.46% recovery) and 151.86 ± 37.61 ng/mL (14.18% recovery)
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from the interval sampled group (data not shown). Statistical analyses showed that there
were no differences in levels released between groups for days 1 through 7 (p>0.05).
However, after day 9, the daily sampled group showed consistently greater levels of
release as compared to the interval group (p<0.05). The rhBMP-2 release from
microspheres exhibited a burst release on day 1 followed by a slow decrease and a steady
state release around 2.5 ng/mL after day 11.
A comparison of the rhBMP-2 released from the composite graft CS2(B4V0) and the
microspheres alone can be seen in Fig. 4. Through day 11, the difference between the
composite graft and the microsphere rhBMP-2 elution was 87-99%. After day 11, the
differences range from 22-62%, with 22% occurring on day 35/36. However, it should be
noted that day 36 for the microsphere group may be reduced because day 35 sample was
lost, and was collected on day 36, thus this is an artificially reduced measurement.

Fig. 4 Elution comparison of rhBMP-2 from composite graft and microspheres (n=5).
Elution day 35 was lost during collection of the microsphere samples, thus day 36 was
collected instead
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Bacteriostatic and Bactericidal Assays with Composite Scaffold Eluates
The ability of eluted samples to inhibit the growth and kill the model bacterium, S.
aureus is shown in Tables 4 and 5 respectively. All groups with 2% vancomycin in the
CS component showed both inhibition of bacterial growth indicated by (-) in Table 4 and
bactericidal activity as indicated by a reduction of ≥ 99.9% of the inoculum of S. aureus
through day 18 indicated by √ in Table 5.

Table 4: Bacteriostatic activity of eluates containing vancomycin against S. aureus
(n=5). (-) indicates no growth, (+) indicates growth and (±) indicates growth or no growth
in replicate samples due to slight variations in drug release at levels near the MIC. All (+)
groups were found to be statistically different from (- and ±) groups (p<0.05).
Days
Group
1 2 3 5 7 8 11 14 18 21 28 35 42
CS2(B0V4)
- - - - - +
+
+
+
CS2(B4V0)
- - - - - ±
+
+
+
CS2(B1V3)
- - - - - ±
+
+
+
CS2(B2V2)
- - - - - ±
+
+
+
CS2(B3V1)
- - - - - ±
+
+
+
CS2(B0V0)
- - - - - +
+
+
+
CS0(B0V0)
+ + + + + + +
+
+
+
+
+
+

Table 5: Bactericidal activity of eluates containing vancomycin against S.
aureus (n=5). (√) indicates that the eluates reduced the number of colony forming units of
the inoculum by 99.9%. All (√) groups were found to be statistically different from (
)
or (*) groups (p<0.05).
Group
1
CS2(B0V4)
√
CS2(B4V0)
√
CS2(B1V3)
√
CS2(B2V2)
√
CS2(B3V1)
√
CS2(B0V0)
√
CS0(B0V0)
* partial killing,

2
√
√
√
√
√
√

3
√
√
√
√
√
√

5
√
√
√
√
√
√

7
√
√
√
√
√
√

8
√
√
√
√
√
√

11
√
√
√
√
√
√

Days
14
√
√
√
√
√
√

no killing
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18
√
√
√
√
√
√

21
*
*
*
*

28

35
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Activity of rhBMP-2 from Composite Scaffold Elution
Difficulties arose when running this assay due to the high calcium and sulfate ion levels
present in the eluates. W-20-17 cell were unable to survive in the presence of these
eluates regardless of antibiotic or growth factor presence (data not shown). These cell
culture difficulties with high calcium and sulfate ion levels have been reported in other
studies [38].
Dual Agent Solution Viability and Activity
Results of the effects of the dual agent solutions on cell viability are shown in Fig. 5
and ALP expression in Fig. 6. There was only a slight, statistical difference in viability
from cells exposed to vancomycin doses at the highest rhBMP-2 dose. For all other
analyses, there were no statistical differences in viability of the cells based on rhBMP-2
dose levels (P=0.586), or vancomycin dose levels (P>0.5), nor was there a significant
interaction (P=0.613). The 1000 ng/mL rhBMP-2 dose level had a statistical difference in
cellular viability. In this group, the viability of cells exposed to the 0 µg/mL vancomycin
level were statistically greater than all other vancomycin containing solutions (P<0.019).
There were no statistical differences in viability of the cells exposed to the other
vancomycin containing solutions. Thus, reduced cell number may influence the data at
1000 ng/mL rhBMP-2 on the ALP graph, however, the trend of reduced ALP with
increased vancomycin concentrations is apparent by 50 ng/mL.
Dual agent solutions, that contained vancomycin concentrations of 1800 µg/ml and
above, did result in a suppression of ALP by the W-20-17 murine cells as compared to
eluates with lower concentrations of vancomycin (Fig. 5). The inhibition of ALP
expression was proportional to the amount of vancomycin in the dual agent solutions
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with highest concentration of vancomycin tested (3600 µg/ml) showing more inhibition
than (1800 µg/ml), whereas the lower levels did not show ALP inhibition. Significant
differences between rhBMP-2 dose level (p< 0.001) and vancomycin dose level (p<
0.001) were indicated as well as significant interaction between the two (p< 0.001). At
concentrations of 100 -1000 ng/mL rhBMP-2, ALP production from cells exposed to
1800 and 3600 µg/mL vancomycin was statistically different from that of cells exposed
to 0 - 450 µg/mL vancomycin (p<0.001).

Fig. 5 W-20-17 cell viability in the presence of rhBMP-2 and vancomycin (n=3). Letters
indicate statistical differences within the 1000 ng/mL rhBMP-2 dosing group, as this was
the only group that showed statistical differences. In the 1000 ng/mL rhBMP-2 level, the
0 ng/mL vancomycin group had a spastically greater viability than the other groups (P <
0.019), however, no other statistical differences in viability for other vancomycin levels
were present
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Fig. 6 ALP production by W-20-17 cells in response to varying levels of rhBMP-2 in the
presence of vancomycin (n=3). Within each rhBMP-2 concentration level, bars with
different letters indicate statistical differences in means for vancomycin levels (p<0.05)

Discussion
A degradable composite graft material, composed of chitosan microspheres (loaded
with rhBMP-2 and/or vancomycin) embedded in CS bone cement (loaded with
vancomycin) was investigated as a dual therapeutic delivery device for infection control
and fracture healing in traumatic bone injuries. In this study, composite grafts and
microspheres alone were evaluated to determine the elution profiles and activity of
released therapeutic agents as well as, an investigation into the interactive effects of
dually delivering a growth factor and antibiotic. Results showed that all scaffold
compositions set in under 36 minutes, and the antibiotic elution exhibited a burst
followed by an extended release that was able to kill S. aureus in vitro for 18 days. The
rhBMP-2 delivery from the composite scaffold was delayed for one day and extended
over 6 weeks. Additionally, it was observed that vancomycin at high levels (3600 and
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1800 µg/mL) inhibited rhBMP-2 as indicated by ALP production from W-20-17 cells
confirming the need for in vitro activity testing of dually delivered therapeutics.
The vancomycin release shown in this work is similar to that of other studies, where
there is an initial burst of antibiotic release followed by a therapeutically active and
extended release [39–41]. All of our composite graft groups were able to release
vancomycin that effectively inhibited growth of S. aureus for 2.5 weeks. It has been
suggested that antibiotic release should last should last 4-6 weeks based the healing times
for the reestablishment of vasculature in bone tissue [2,6,39,41]. While the release in this
study was 1.5 weeks shy of this suggested timeframe, our dosing level of 2% is also
lower than a common clinical dosing of 3.64% vancomycin [16,18]. We chose this lower
dose to reduce potential interactions of vancomycin with rhBMP-2. Increasing the
vancomycin loading could extend the therapeutically active release into the 4-6 week
timeframe without much if any inhibition of rhBMP-2 due to the delay in growth factor
release that we detected from the scaffold. Nevertheless, the composite showed nearly
complete vancomycin recovery at 18 days (98.94 ± 2.68% recovery) and 42 days (99.32
± 2.37% recovery) suggesting a low potential for contributing to bacterial resistance due
to extended subtherapeutic levels.
Due to the low elution of rhBMP-2 from the composite grafts (~1 ng/mL/time point
for the highest loaded group CS2(B4V0)) it is suspected that the majority of the rhBMP-2
loaded into the microspheres may have been retained by the calcium components of the
graft. The affinity of rhBMP-2 for calcium phosphate materials has been previously noted
in literature [29,42,43], and from the results of the microsphere elution where the rhBMP2 release was found to be on average 72% greater than the rhBMP-2 release from
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composites we confirm our findings. Even though the rhBMP-2 elution from the
composite was not enough to elicit a noticeable ALP increase in W-20-17 cells, a general
trend of the rhBMP-2 release was found to be directly proportional to the loaded amount
of growth factor. However, due to the variability in the amount of agents eluted from the
composite scaffold, statistical differences were not consistent between groups at all
evaluation time points. The elution profile from the microspheres was similar to that of
Reves et al., where rhBMP-2 elution from lyophilized chitosan microspheres was
sustained for 26 days [33]. Overall, affinity of rhBMP-2 for calcium materials may be a
technique for localizing delivery to a specific area [38]. We hypothesize that in vivo, the
calcium sulfate graft will dissolve releasing the bound growth factor at a prolonged
higher dose, and further animal testing is needed to investigate this hypothesis.
Additionally, daily and intermittent sampling methods were tested with rhBMP-2 elution
from microspheres, and results found a 40% increase in detected rhBMP-2 in the daily
sampled group compared to the intermittently sampled group. This measured decrease is
most likely a result of rhBMP-2 denaturing over time, particularly over the larger interval
times (4-7days) and may cause an underestimated amount of active rhBMP-2 released
from scaffolds sampled intermittently [27,29,44]. Thus, future in vitro elution studies
with rhBMP-2 should be sampled every day to avoid this reduction in activity.
Despite the reported issues (fast resorption and lack of strength), calcium sulfate has
been a successful device for bone regeneration and infection control [25,36]. There is
further potential for calcium sulfate to be used in a combination device, as we
demonstrated with chitosan microspheres due to the retention and delivery of rhBMP-2
locally in a wound area. Calcium sulfate has been shown to exhibit surface dissolution of
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ions into the surrounding medium [45]. In our study, this scaffold dissolution left
noticeable precipitation in all of the elution samples and caused an ionic imbalance in our
cellular studies [38]. Thus, there was reduced viability in cells containing eluates from
the composite scaffolds compared to controls in growth medium only (p<0.05, data not
shown). This is unfortunately a consequence of static tissue culture, however it is
important to note that in vivo calcium sulfate is considered biocompatible due to the
accelerated and successful regeneration of bone [36,46,47].
It has been previously shown that high levels of antibiotics can cause cell death in
vitro or tissue toxicity in vivo [48,49], thus, it is important to address the potential effects
of the released antibiotic on the bioactivity of rhBMP-2 To do this dual agent solutions of
rhBMP-2 and vancomycin were made in a range to cover the values measured from the
elution study and values known to stimulate ALP expression in W-20-17 cells. The
results showed that higher levels of vancomycin (1800-3600 µg/mL) interfere with
rhBMP-2 stimulated osteogenesis observed by the reduction in ALP. Thus, interactive
effects of therapeutic agents should be considered in dual delivery systems in order to
provide the most effective doses and clinical outcomes. It should be noted that in vivo,
the highest levels of vancomycin are typically released from scaffolds in the early time
points when inhibitory effects on rhBMP-2 would be at a maximum. However, the lack
of osteoprogenitor cells in the wound site at his stage is minimal so this initial inhibitory
effect may not be critical, especially if the rhBMP-2 release is delayed [50–52].
Tobramycin and rhBMP-2 were both evaluated in vitro and in vivo as a dual delivery
system by Glatt et al. In a rat model, Glatt successfully showed healing with a collagen
sponge delivery system carrying both agents, however, in vitro, they found a dose
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dependent reduction in rhBMP-2 activity with increasing tobramycin concentrations,
similar to our study [23]. Similarly, Wang et al. also showed significant bone
regeneration in vivo (>14 days) for calcium sulfate composites loaded with vancomycin
and rhBMP-2 compared to controls. However, Wang et al. did not report any inhibitory
effects of the dual agents in vitro, probably because they did not have sufficient controls
or time points to evaluate agent interactions [25]. While both studies were able to support
the beneficial effects of rhBMP-2 in vivo only one evaluated the interactions the dually
delivered agents. Thus, dual delivery systems are a viable option for efficient fracture
healing in the presence of antibiotics and it remains important to determine the reactivity
of the agents in order to achieve an appropriate dosing scheme and thus reduce the cost
and improve the efficiency of healing.
Conclusion
In this study, we showed that the chitosan/calcium sulfate scaffold was able to
deliver both an antibiotic and a growth factor in vitro over a clinically relevant time
period. The model therapeutics used in this study, vancomycin and rhBMP-2, are
representative of treatments that are necessary for simultaneously preventing infection,
regenerating tissue and reducing healing complications in large bone defects. The
extended antibiotic release exhibited in this work is important to eliminate and prevent
infections that could interfere and delay healing in contaminated fracture wounds.
Additionally, the ability of this graft material to extend the rhBMP-2 delivery is crucial to
overcome the challenges of regenerating bone in large defects. The decreased cellular
response to rhBMP-2 in the presence of high levels of vancomycin reinforced the
necessity to evaluate drug interactions in dual delivery systems in order to achieve
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optimal therapeutic outcomes. In summary large fracture wounds, where the vasculature
is often compromised, require multiple factors to aid in tissue repair and infection
control. Our research reports the effective dual delivery from a degradable bone scaffold
while supporting the need to investigate the potential interactions of co-administered
pharmaceutical agents.
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CHAPTER 4
EVALUATION OF A CALCIUM SULFATE-CHITOSAN FIBER-MESH
SCAFFOLD AS A DUAL DELIVERY BONE SCAFFOLD FOR RHBMP-2 AND
VANCOMYCIN

Introduction
A recent study estimated that over $5 billion dollars per year will be spent in the US
alone for treating severe orthopaedic traumas including bone excisions, grafting and
fracture repair 1. Orthopaedic traumas may become infected with a variety of pathogenic
bacteria at the time of injury, while in the hospital, or afterwards during healing. Wound
healing in patients with infected orthopaedic fractures is complicated and continues to
plague the medical community. Infections have been reported in as many as 60% of
battlefield open fracture wounds and 65% of civilian open fractures 2,3. Infections at the
site of orthopaedic traumas can lead to multiple surgeries, extended antibiotic treatment,
limb amputation, and even patient death 3–5. Treatment of infected bone is particularly
challenging due to compromised vasculature, especially in devastating traumatic injuries
with substantial tissue damage where the immune response and systemic antibiotic
treatment are cut off from the wound site 6. Thus, there is a critical need for therapies that
fight/prevent infection and stimulate bone regeneration to aid in healing of large, infected
orthopaedic fractures. Ideal dual delivery systems for treating infected fractures should
have the following key characteristics: degrades at the same rate as healing,
controls/sustains the release of growth factors, extends the release of antibiotics, is
customizable for individualized care and maintains mechanical integrity to support
regeneration in a critical size defect 7–10.
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To address this challenge several studies have investigated the dual delivery of a
growth factor, BMP-2, and antibiotics from bone grafts and coatings 5,11–18. These studies
investigated, BMP-2 because of its potent osteoinductive properties 19–22, in combination
with different antibiotics such as vancomycin, teicoplanin, and gentamicin 5,11–18. Wang
et al. investigated BMP-2 and vancomycin loaded into CS pellets and found that BMP-2
was active for 29 days in vitro and that rabbit tibial defects had significantly more new
bone growth after 28 days in the presence of scaffolds loaded with both factors over
controls. While Wang et al. demonstrated that both therapeutic agents could be extended
over several weeks, the activity of the antibiotics was not tested, and the use of
supraphysiological doses (50 μg – 60 mg) of BMP-2 increases the cost of treatment and
raises concerns about safety and negative side effects such as ectopic bone formation
21,23–25

.

The co-delivery of low-dose BMP-2 and vancomycin from a composite pHEMAnHA scaffold was evaluated in vitro and in vivo 14,15. The BMP-2 release in vitro from
these scaffolds containing 300 ng BMP-2 and 4.8% vancomycin was relatively fast with
95% eluted over 48hrs 14. However, full bridging in femoral rat defect after 12 weeks was
found with a pHEMA-nHA scaffold with 3 µg BMP-2 and 4.8% vancomycin 15. While Li
et al. reported a burst and 2 week extended elution of vancomycin from the dual loaded
pHEMA-nHA scaffold, activity against E.coli was only established for 48 hr, and activity
was not tested in vivo by Skelly et al. 14,15. Thus, even though low levels of BMP-2 were
shown to repair bone in vivo, the effectiveness of antibiotics over an extended period was
not evaluated, nor could these scaffolds be easily customizable since they require several
days to prepare. Guelcher et al. reported modest and low burst levels of BMP-2 and
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vancomycin from a PUR scaffold after 5 days followed by an extended 21-day release in
vitro. They also evaluated the dual-delivery graft in an infected femoral rat defect and
found that PUR scaffolds loaded with either 2.5 µg or 25 µg BMP-2 and vancomycin had
more bone growth than either a collagen control or non-antibiotic loaded group after 8
weeks 18. Guelcher et al. was able to show extended therapeutic delivery and excellent
translation in an animal model. However a shortcoming of their work was inconsistent
scaffold degradation, which could prevent tissue regeneration. The above studies show
that the co-delivery of BMP-2 and vancomycin can be successful in regenerating tissue
and fighting infection, but continue to have shortcomings in one or more areas such as
controlled and sustained drug release, degradation rate equal to tissue regeneration and
customizability.
We have investigated a composite scaffold made from a calcium sulfate matrix
reinforced with a chitosan fiber-mesh to determine if it will meet criteria for effective
dual delivery of a growth factor and antibiotic from a bone scaffold. CS is an approved
FDA device, that degrades at a rate similar to bone regeneration, is biocompatible, and
can deliver clinically relevant doses of antibiotics (such as cefazolin, vancomycin,
gentamycin) in vivo for several weeks 26–33. Due to the favorable cellular and tissue
response in vitro and in vivo, chitosan, has been widely studied for biomaterial
application and has been shown to be a good carrier for many therapeutic agents 34–36.
Previous work in our lab has reported >90% retention of BMP-2 from CS/chitosan
scaffolds over 6 weeks. In order to increase the BMP-2 elution while maintaining the
favorable elution kinetics (reduced burst and extension) a chitosan fiber-mesh was
investigated. It has been reported in the literature that resorbable fibers create
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interconnected pores throughout calcium phosphate cements (CPC) as they degrade 37–40.
These interconnected channels extend into the interior of the ceramic matrix and may
allow for diffusion of growth factor from the interior of the scaffold and enhanced tissue
ingrowth 37,38,40,41. Additionally, research has shown that chitosan fiber-reinforced
scaffolds were able to increase compressive and flexural strengths with calcium
phosphate and collagen based scaffolds 42–44. Increased mechanical strengths would be
beneficial for load bearing applications, to provide a 3D platform for cellular attachment,
and to facilitate new bone growth.
Additionally, the composite graft may be prepared on the bench as a point-of-care
device to enable the surgeon to customize it with desired antibiotics and growth factors.
The chitosan fiber-mesh may be pre-loaded with physician selected growth factors or
other therapeutic agents via swelling. An antibiotic or other therapeutic agent may be
added to CS and fiber-mesh individually prior to combining into a single composite. The
growth factor rhBMP-2 will be used as a model growth factor and loaded into the
chitosan fiber-mesh component. The antibiotic, vancomycin, will be used as the model
antibiotic and mixed into the CS component. Chitosan lactate will also be investigated as
a mechanism to improve binding of the fiber-mesh within the CS matrix. We
hypothesized that 1) the eluted antibiotics will be active against bacteria for 4-6 weeks, 2)
incorporation of rhBMP-2-loaded chitosan mesh into the CS will delay and extend the
growth factor release, 3) chitosan lactate incorporation will improve the binding between
chitosan mesh and CS matrix and 4) the addition of chitosan fiber-mesh will improve the
mechanical properties of the scaffold.
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Materials and Methods
Chitosan Fiber-Mesh Fabrication
Chitosan fiber-meshes were fabricated with a co-precipitation wet-spinning method
based on a bead fabrication method45. Briefly, a solution of 3% chitosan (80% DDA, 260
kDa, Primex EHF, Siglufjordur, Iceland) was prepared in 2 wt% acetic acid solution.
After 24 hours, the solution was strained through a fine mesh to remove any undissolved
chitosan flakes and loaded into a syringe with a 21-gauge needle. The syringe was loaded
into a pump and extruded continuously (>0.8ml/min) into a solution of 20% NaOH, 30%
methanol, and 50% deionized (dI) water (pH=13). The fibers were extruded into the base
as it rocked on a Belly Dancer shaker at 2 RPM. After wet spinning, the mesh was
washed with deionized water (dIH2O) until a neutral pH was achieved (pH 7-8). Using a
8mm punch, meshes were cut, air dried, and sterilized with ethylene oxide gas.
Scaffold Preparation and Therapeutic Agent Loading
Composite scaffolds were made with 0.53g α-hemihydrate Calcium Sulfate (CS)
(Wright Medical Technologies, Inc, Arlington, TN) and either 4% or 7% chitosan fibermesh (by wt to CS powder). Chitosan lactate (L) (85 ± 2% DDA, ~500kDa, Dungeness
Environmental, Bothell, WA) was hydrated with dIH2O one day prior to use and used to
manufacture half of the scaffold formulations with a final concentration of 1%. For
composite scaffolds containing growth factor, 10 µg rhBMP-2 (0.35 g/mL) (PeproTech,
Rocky Hill, NJ) was added to fiber-meshes by complete adsorption of rhBMP-2 prior to
mixing into composite formulations. Vancomycin hydrochloride (MP Biomedical, Solon,
OH) was added into the CS at 2% wt (CS:H2O ratio of 4:1) directly before mixing into a
scaffold. All scaffolds were made by combining CS or CS and CL with chitosan meshes
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into a mold and thoroughly mixing for 40 stirs in 20 seconds. The mold was tapped 20
times on the bench to remove air bubbles and allowed to set for 1 hour at room
temperature. All elution samples were prepared in a silicone mold 6.4mm diameter x
15mm high (n=5/group). Seven scaffold compositions were evaluated, Table 1.

Table 1: Scaffold compositions.
Vancomycin rhBMP-2 loaded 1% chitosan
Group
loaded CS chitosan Mesh %*
Lactate
C (control)
X
CL
X
X
(control)
M (control)
4
C4M
X
4
C7M
X
7
CL4M
X
4
X
CL7M
X
7
X
*Set tests used α-chymotrypsin as a model for of rhBMP-2

Mechanical Tests
Set time, compression and three-point bending experiments were performed to
evaluate mechanical properties of the scaffolds based on the addition of chitosan fibermeshes, calcium lactate, and incorporation of therapeutic agents.
Viacat Hardness Set Test
A set test adapted from Doty et al. and ASTM Standard C472.26 was performed with
the Viacat apparatus (Standard Test Methods for Physical Testing of Gypsum, Gypsum
Plasters and Gypsum Concrete, ASTM, Inc., PA, USA) 39. In the test, the distance the
Viacat needle (1mm diameter) penetrates the surface of the specimen was measured
every 30 seconds. The time at which the needle penetrated less than ½ the height of the
sample was used as the set time. Tests were performed in triplicate. Mixing dishes 37mm
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diameter x 12 mm high were used to manufacture test specimens to provide sufficient
area for repeated Viacat needle penetration measurements tests. α-chymotrypsin (from
bovine pancreas, Sigma, St. Louis, MO) was used in place of rhBMP-2 for these tests due
to the high amount of protein needed for the large specimen size. α-chymotrypsin was
used as a model for rhBMP-2 since the MW and pI for the two proteins are similar: αchymotrypsin, MW: 25kDa, pI: 8.725 (Sigma-Aldrich Product Info), rhBMP-2, MW:
26kDa (PeproTech Product Info) and pI: 8.2-8.66 23,46–48.
Compression Test
For compression tests, stainless steel molds of 6mm diameter x 12mm long were used
to manufacture test and control specimens. Two plates were placed on top and on the
bottom of the mold and the plates were secured with clamps. After 1 hour the top and
bottom plates were removed and the surfaces were made flat with a razor blade and
samples were removed from the mold. Samples were stored at room temperature until
testing. The samples were tested on an MTS Insight 50 Test System using Testworks 4
software and a 5kN load cell and an adjustable anvil to accommodate non-parallel
specimen ends. Samples were tested with the longitudinal axis in a vertical orientation at
a displacement rate of 0.33 mm/sec until failure. The software automatically stopped the
compression test when loads over 1000N dropped more to than 20% of the peak force
(N). Controls were performed in replicates of 8, while all other experimental groups
containing rhBMP-2 were tested in triplicate. Reported values for compression tests were
normalized to present a material property independent of the scaffold shape. The
maximum force, F, was used to calculate the ultimate compressive strength (UCS), σUCS
= F/A where A = cross sectional area. The compressive modulus (MPa) was determined
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from the linear part of the force displacement curve and the strain energy density (MJ/m3)
was calculated from the area under the stress strain curve up to the failure point. The
failure point was defined as the maximum stress for samples with a brittle fracture, and at
2% strain for samples with extended mechanical integrity. The 2% strain cut off point for
the area under the curve calculation was based on features in the stress strain curves.
Three-Point Bend Test
Three-point bending test specimens were made using silicon molds with dimensions
6.4 mm diameter and 44 mm long. After 1 hour samples were removed and stored at
room temperature until testing. Tests were performed using an Instron Model 33R 4465
with Bluehill® Software. A fixture span of 30 mm, crosshead speed of 1 mm/min, and a
500N load cell were used. Tests were stopped when the load dropped more than 40%.
Control and lactate containing experimental groups were tested in triplicate and nonlactate experimental groups were tested in quadruplicate. The load at break (N) was
recorded and flexural strength, σfs, (MPa) calculated based on Eq 1. The work (J) was
determined by calculating the area under the load displacement curve up to the failure
point. The failure point was defined as the maximum load for samples with a brittle
fracture, and at a displacement of 0.19 mm for samples with extended mechanical
integrity. The cutoff point of 0.19 mm was chosen because that was the displacement for
other samples that had a brittle fracture break.
! !

!
!!" = !!
!

Where Fm= maximum load, L = length of support span, R = radius of cylinder.
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(1)

Antibiotic Elution, Growth Factor Elution, and Scaffold Degradation
The concentration of eluted rhBMP-2 and vancomycin from the scaffolds was
evaluated by placing scaffolds (n =5/group) in 1.6 mL of high glucose DMEM at 37oC.
Eluates were collected every day for 6 weeks and stored at -80oC until analyzed. At every
collection, the medium was completely replaced with fresh medium. Eluates were
measured with an Enzyme-Linked Immunosorbent Assay (ELISA) (PeproTech, Rocky
Hill, NJ) and Fluorescence Polarization Immunoassay (FPIA) (TDxFLx, Abbott
Laboratories) to detect rhBMP-2 and vancomycin respectively 39,49,50. Additionally, 4
samples were prepared as described in section 2 similar to C7M using fluorescently
labeled rhBMP-2 to observe the location and retention of growth factor in the scaffold at
2, 4 and 6 weeks. rhBMP-2 was fluorescently tagged with Alexa Fluor® 568 (Molecular
Probes, Inc. Eugene, OR) following manufacturer’s instructions using a Micro BioSpin® column (Bio-Rad, Hercules, CA). Scaffolds were incubated in DMEM with
medium changes and at day 0, 2, 4 and 6 weeks (n=1/time point) were cut into 2mm
slices with an IsoMet 100 precision saw and diamond blade (Buehler, Lake Bluff, IL) and
visualized with a confocal microscope (Nikon Ti-E A1rSi) with TRITC filter. Samples
were normalized to a control composed of the same scaffold material but containing no
labeled protein. Mass of the scaffold was recorded prior to and post elution. Percent
degradation, and therapeutic agent release were calculated with Eqs. (2) and Eqs. (3)
respectively.

% !"#$%&%'()* =

!"#$#%& !"##!!"#$% !"##
!"#$#%& !"##
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∗ 100

(2)

% !ℎ!"#$%&'( !"#$% !"#$%"!& = 100 −

!! !!!
!!

∗ 100

(3)

Where TL = Theoretical amount of loaded therapeutic agent and TC = Cumulative
therapeutic agent release over 42 days. The theoretical amount of both rhBMP-2 and
vancomycin was calculated based on the amount that was loaded into each scaffold.
Antibiotic Activity
The antibacterial activity of eluted vancomycin was tested by turbidity assays as
previously described 39,49. Briefly, tubes containing 1.75 mL of trypticase soy broth
(TSB) were inoculated with 25 µL containing ~2x106 colony forming units (CFU) of
Staphylococcus aureus (Cowan I strain, ATCC 12598, Manassas, VA) and 200 µL of
scaffold eluates. Control tubes were made with 1.75 mL TSB, 200 µL of DMEM
medium, and either 25 µL of S. aureus (positive) or 25 µL of TSB (negative). Tubes were
incubated overnight at 37oC and the turbidity was measured spectrophotometrically
(Spectronic Instruments, 20 Genesis) at OD530. Optical density (OD) values < 0.05 were
considered as “no-growth”.
Statistical Analysis
Statistical analysis was performed with ANOVA for all mechanical tests and
degradation analysis. Factorial analysis of variance was used to determine effects of the
presence of lactate, and percentage of mesh on the release of drugs from the composite
scaffolds over time. When statistical differences were detected, post hoc analysis was
carried out with Student –Newman-Keuls (SNK, P<0.05). Statistical analysis of turbidity
results were performed with a proportions test using contingency tables for the rate of
inhibition of growth with a Fishers Exact test. When normality assumptions were violated
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for ANOVA tests, a non-parametric Kruskal-Wallis test was performed. Statistical
analyses were conducted using SigmaPlot 12.5 at α = 0.05 level of significance.
Results
Chitosan Fiber-Mesh and Scaffold Fabrication
Wet spun chitosan meshes exhibited fibers diameters of 129 ± 16 µm after air-drying.
The air-dried meshes were stiff and brittle until hydrated. The mixing of CS-chitosan
mesh scaffolds resulted in a wet-slurry that could not be manipulated by hand. When CL
was added to the scaffolds, a dough-like material was rapidly formed and was easily
manipulated by hand. Slurries and dough were easily added to molds and after drying
scaffolds maintained their shape when removed from molds. The dry molded scaffolds
were robust and did not crumble when handled (Fig. 1).

Fig. 1 Digital microscopy images (Keyence VHX-1000) of calcium sulfate powder (a),
chitosan fiber-mesh (b), and side and top view of cylindrical composite pellet of chitosan
mesh incorporated into calcium sulfate (c).

Mechanical tests
Viacat Hardness Set Test
The Viacat set test resulted in set times between 10-42 minutes depending on scaffold
composition (Fig. 2). A two-way ANOVA indicated that there were significant
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interaction between wt% of chitosan mesh and the use of chitosan lactate. Subsequent
analysis indicated that the addition of chitosan lactate caused a significant reduction in set
time of the CL group as compared to the CS control (p<0.001). Similarly, the presence of
lactate caused a reduction in set time for both the 4 and 7% mesh composites (p<0.001).
However, there was no effect on set time between the 4 and 7% mesh composites either
with or without chitosan lactate (p=0.09). Interestingly, set times were statically greater
for mesh composites without lactate as compared to plain CS controls (p<0.001).

Fig 2. Set time as determined by Vicat, in minutes. All groups are statistically different
from each other (p<0.05) except those marked by symbols (#) which indicate no
differences p=0.09.

Compression Test
Representative force-displacement curves and fractured specimens from compression
tests are shown in Fig. 3. The control (C and CL) test specimen exhibited typical brittle
behavior, in which specimens fractured and lost mechanical integrity rapidly after
exceeding peak loading forces (Fig. 3a, 3c). The visible fracture pattern for control
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samples (Fig. 3a) showed cracking at the top and through the sample, but did not shatter
in the test frame. Upon removing from the test frame, scaffolds did break into several
pieces (not shown). However, when meshes were incorporated in the CS matrix, the
specimens were able to continue to maintain some mechanical integrity after peak
loading forces. These samples exhibited crushing type failures (Fig. 3b, 3d) and did not
further break upon removal from the test frame.

Fig. 3 Fracture patters (a, b) and representative force displacement curves (c, d) of
scaffolds after compression. Representative break patterns of (a) control samples (C, CL),
chipping on top exterior is noticeable, (b) chitosan mesh containing scaffolds (C4M,
C7M, CL4M and CL7M), sample is crushed and chitosan mesh is visible, (c) force
displacement curve for control samples, brittle break (d) force displacement curve for
chitosan mesh containing scaffolds, crushing failure with extended mechanical integrity.

Values for UCS, compressive modulus and the strain energy density are shown in Fig.
4. Scaffolds containing mesh exhibited significantly lower UCS and compressive moduli
compared to controls, C and CL (p<0.001). C exhibited the highest UCS and compressive
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modulus compared to all other groups (p<0.001). There were statistically significant
interactions between mesh and chitosan lactate presence within UCS and strain energy
density analysis. Further analysis of UCS revealed some difference within the groups
containing mesh, but these differences were small compared to the differences between
the controls. The compressive modulus for CL7M was lower than all other mesh
containing groups (p<0.003). In contrast to the large difference found between controls
and mesh containing scaffolds for UCS and compressive modulus, the strain energy
density from scaffolds containing 4% mesh were similar to that of the CS without lactate
control group. The strain energy density was lowest for the 7% mesh groups and the CS
with lactate control. The CL and 7% mesh groups had the lowest strain energy densities
(p<0.050) though C7M was not statistically different from the C4M (p = 0.065).
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Fig. 4 The effect of chitosan mesh and chitosan lactate on mechanical properties from
compression tests. (a) UCS (MPa), (b) compressive modulus (MPa), (c) strain energy
density (MJ/m3). Dashed lines indicate the statistical differences across all groups unless
otherwise marked. Symbols indicate statistical differences *p<0.001, **p<0.01, ***
p<0.05.
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Three-Point Bend Test
Representative force-displacement curves and fractured specimen for three-point bend
tests are shown in Fig. 5. Fig. 5a and 5c show the brittle break typical of control samples.
Scaffolds that contained meshes remained intact after fracture (Fig. 5b), but a fracture
could be seen while the specimens were in the test frame. Mesh containing scaffolds had
force displacement curves represented in Fig. 5d, 6 samples had brittle fractures (d1), 2
samples had a small break followed by extended mechanical integrity (d2), and 4 samples
had jagged breaks (d3).

Fig. 5 Fracture patters (a, b) and representative force displacement curves (c, d) of
scaffolds after three-point bending tests. Break patterns of (a) control samples (C, CL)
exhibited brittle breaks, (b) chitosan mesh containing scaffolds (C4M, C7M, CL4M and
CL7M) showed no visible break after test completion though specimen did crack during
testing. Representative force displacement curves showed a brittle break for control
samples (c) and three different types of fractures for mesh containing scaffold ranging
from brittle break (d1, n = 6), to small break followed by extended mechanical integrity
(d2, n=2), or jagged break (d3, n=4).

Similar to the compressive test results, the three-point bending results showed
decreasing load at break and flexural strength as the chitosan mesh percentage increased

76

(Fig. 6). However, the presence of chitosan lactate did not seem to have any effect on
scaffolds in three-point bending. The control groups had statistically higher loads and
flexural strengths at break compared to mesh containing groups p<0.001 (Fig. 6a, 6b).
The scaffolds with 4% mesh had higher loads at break and flexural strengths than
scaffolds containing 7% mesh (p<0.01). There were no statistically significant differences
between the controls (C and CL) and any of the test composite scaffolds (Fig. 6c).
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Fig. 6 The effect of chitosan mesh and chitosan lactate on mechanical properties from
three-point bend tests. (a) Load at break (N), (b) flexural strength (MPa), (c) work (10-3
J). Dashed lines indicate the statistical differences across all groups. Symbols indicate
statistical differences *p<0.001, **p<0.01, *** p<0.05.

Antibiotic Elution, Growth Factor Elution, and Scaffold Degradation
All scaffolds exhibited a typical burst release of vancomycin on the first day followed
by a decrease in elution thereafter (Fig. 7). Statistical analysis found that the release of
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vancomycin from scaffolds was dependent on both the wt% of chitosan mesh and
presence of chitosan lactate. To evaluate the scaffolds, subsequent factorial analyses were
performed for groups at individual time points. The elution from CL7M was statistically
different from all other groups on day 2 and from some other groups at days 3 and 4 (Fig.
7a). Similarly CL4M eluted more vancomycin than various other groups on days 4, and
days 7 to 14 (p<0.05). However the general trend was that CL7M exhibited the highest
vancomycin release over the first 4 days and fastest release compared to other groups
such that by day 10 the elution levels were negligible. Scaffolds containing 4% mesh
exhibited a longer and higher vancomycin release (day 6-20) as compared to the 7%
mesh groups. The control scaffolds (scaffolds without mesh) exhibited the longest elution
release profiles with the highest vancomycin release from days 8-42 (p<0.05).
Vancomycin recovery was 98% at: day 7, 8 for CL7M, CLM; day 12, 17 for C4M,
CL4M; day 17 for both C, CL. The total recovery of vancomycin from all control and test
composite scaffolds ranged between 81-90% (Table 2).
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Fig. 7 Vancomycin elution from composite scaffold. (a) Day 1-10 (b) day 11-30.
Symbols indicate statistical differences *p<0.01, ** p<0.05.

Table 2 Scaffold growth factor/antibiotic recovery, and % degradation over 6 weeks.
% BMP
% Vancomycin
Group
% Degradation
Recovery
Recovery
C4M
1.13 ± 0.01
88 ± 3
83 ± 3
C7M
1.04 ± 0.01
81 ± 8
83 ± 2
CL4M 0.69 ± 0.01
91 ± 18
65 ± 13
CL7M 0.89 ± 0.01
91 ± 16
68 ± 15
C
na
93 ± 5
72 ± 2
CL
na
77 ± 5
71 ± 1
M
10.63 ± 0.04
na
nd
na = not applicable because drug not in scaffold. nd = not determined, determined for
composite scaffolds only.
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Results of rhBMP-2 release from scaffolds and chitosan mesh are shown in Fig. 8.
Chitosan mesh samples loaded with rhBMP-2 but not incorporated into CS, exhibited a
burst release on day 1 and a non-uniform but degrading release rate over 42 days (Fig.
8a). Comparatively, all the rhBMP-2 loaded mesh that were incorporated into the CS
exhibited a gradual increase in rhBMP-2 release over the first 5-7 days followed by a
more sustained low-level release over the remainder of the study (Fig. 8b). By day 23, the
rhBMP-2 release from M was similar to the levels recorded for the composite scaffolds.
Initially lower levels of rhBMP-2 were released from scaffolds containing chitosan
lactate (d3-18), but statistical differences were not detected at every time point, nor did
they follow a consistent pattern. No statistical differences were found in the elution of
rhBMP-2 after day 23 for any groups. The total recovery of rhBMP-2 from the composite
scaffolds (~1%) and chitosan mesh (~10%) was very low (Table 2). Images from
scaffolds with fluorescently tagged rhBMP-2 showed rhBMP-2 remained in scaffolds
after 42 days (Fig. 8c).
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Fig. 8 Elution of rhBMP-2 from all composite scaffolds over 42 days (a) control
compared to composite scaffolds (b) composite scaffolds only, (c) confocal microscope
image from scaffolds loaded with fluorescently labeled rhBMP-2, arrows indicate
chitosan mesh and black space is calcium sulfate.

While not statically significant, the scaffolds containing chitosan mesh but no chitosan
lactate (C4M/C7M) appeared to degrade more (~82%) than the control groups (~71%),
indicating that the mesh contribute to the scaffold degradation (Fig. 9 and Table 2).
Additionally, CL4M and CL7M were not statistically different from controls, and did not
expose as much of the chitosan mesh as C4M/C7M did (Fig. 9). Statistically significant
differences were found between C4M-CL4M (p=0.008) and C7M-CL7M (p=0.029) but
not between C-CL (p =0.786).
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Fig. 9 Digital microscopy images (Keyence VHX-1000) of degraded scaffolds after 42day elution study. (a) C, (b) C4M, (c) CL4M, (d) CL, (e) C7M, (f) CL7M.

Antibiotic Activity
The eluates from scaffolds without mesh (C, CL) had the longest duration of inhibiting
growth of S. aureus at 22 ± 4 days compared to all other groups (Fig. 10). The inhibition
from C and CL was statistically significant (p=0.02) for all groups except CL4M. The
elution from scaffolds with 4% mesh exhibited longer bacterial inhibition (16 ± 4 days)
over scaffolds with 7% mesh, but only the groups with chitosan lactate (CL4M/CL7M)
were statistically different (p=0.027). Groups containing 7% mesh (C7M, CL7M) had the
lowest duration of bacterial inhibition of growth averaging 10 ± 2 days.
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Fig. 10 The length of time that the eluates from all scaffolds inhibited growth of S.
aureus. Symbols indicate statistical differences *p<0.001, **p<0.01, *** p<0.05.

Discussion
The challenge in developing materials to treat infected bone defects is to 1) load
and deliver maximally active therapeutic concentrations with minimal doses to eliminate
infection while stimulate bone growth, 2) maintain mechanical integrity to allow for bone
regeneration and tissue ingrowth, and 3) allow customization to accommodate the needs
of individual patients. To address these needs the present work evaluated the effects of
chitosan mesh and chitosan lactate incorporation into a CS matrix on mechanical
properties, antibiotic and growth factor elution, and antibiotic activity. To the best of our
knowledge this is the first study to evaluate the mechanical properties and dual-elution
properties of a therapeutically loaded CS - chitosan mesh scaffold.
CS was evaluated in this study since it is a well-known bone scaffold material that
facilitates new bone regeneration and has good drug delivery properties 26–29,31,51. We also
incorporated chitosan in both fiber-mesh and gel form since it is a versatile biomaterial
for wound healing; tissue regeneration and drug delivery 34–36,52. The use of chitosan
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lactate with the CS scaffolds had a clear effect on increasing set time in our study which
is not surprising since it has been used to help make fast-setting and washout resistant
CPC scaffolds by reducing the fluid penetration into the scaffold 53–55. Additionally,
chitosan has been used as a binder for scaffold materials and has been found to increase
mechanical properties in CPC cements 36,40,53,56–58. We found the presence of chitosan
lactate did not consistently aid or inhibit the binding of chitosan fiber-mesh to the CS
matrix as determined by mechanical tests, but instead increased the handleability through
the formation of a workable dough, which could be of benefit in the operating room. The
incorporation of higher percentages of mesh into the scaffolds resulted in increased
pathways along which fluid could penetrate into scaffold, increasing drug release and
dissolution of the scaffolds. The pathways created by the fibers increase the porosity of
the bulk material, and increased porosity has been reported to increased drug elution as
well as degradation59–63. This is supported by our findings of increased vancomycin
elution from scaffolds as mesh percentages increased in the scaffolds, and by the change
in degradation from surface erosion as seen in control samples compared to bulk
degradation seen with mesh containing scaffolds. Some of the variation in our
degradation and antibiotic elution results were likely a result of hand making our
scaffolds. This is attributed to the fact that the chitosan lactate groups set faster than other
groups, giving less time for mixing and thus perhaps were less uniform. However, in the
setting of an operating room, the ability to manipulate a material by hand and into a nonuniform wound void may be more advantageous than making uniform samples.
The fracture break patterns of samples in compression were similar to those
reported by Zhao et al., where there was non-catastrophic failure followed by an extended
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ability to withstand a load 64. The three-point bending data clearly demonstrated the
ability of the chitosan mesh scaffolds to remain intact after fracture, which would be
beneficial in a wound to increase break/washout resistance and to be able to deliver drugs
at the specific area of need. The difference between percentages of chitosan mesh was
most clearly seen in the load to break and flexural strength from three-point bending
tests, with 4% scaffolds being stronger than 7% scaffolds. Pan et al. also found a decrease
in flexural strength with an increase in chitosan fibers in a CPC scaffolds likely because
of non-uniformly distribute fibers and high air voids 65.
We found that after incorporation of both the chitosan mesh and the chitosan
lactate, there were no improvements over control groups in compression or three-point
bending properties unlike other studies that found higher compressive and flexural
strengths for chitosan fiber reinforced scaffolds compared to controls 42–44. We suspect
that this is because the surface area of our chitosan mesh is much larger than that of
individual fibers and may not have integrated as well with the CS. Only in the strain
energy density for compression and work for three-point bending did some chitosan mesh
and chitosan lactate containing scaffolds have similar properties to those of chitosan
sulfate controls, indicating a benefit in chitosan mesh incorporation. The flexural strength
(16-18 MPa) and UCS (22-28 MPa) for scaffolds containing 4% mesh were very similar
to reported values of flexural strength (7-10 MPa) for poly(D,L-lactide-co-glycolide)–
CPC scaffold and of UCS (33 MPa) for chitosan fiber reinforced- CPC cements
respectively 43,66. While these strengths are significantly lower than the reported
compressive strengths required for femur defects or vertebra spacers (133 MPa), they are
still applicable for non-load bearing orthopaedic and craniofacial applications 66,67.
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The vancomycin elution for all groups exhibited a typical burst release followed
by a prolonged decay, as reported in other studies 39,68–70. CL7M had the quickest elution
over the first few days, possibly due to an increased porosity associated with the meshes
and a possible interaction with chitosan lactate. For 7% M groups, the eluted vancomycin
levels fell below the MIC for S. aureus (0.5-1µg/mL) between day 18-19, between day
20-25 for 4% M groups and between day 27-30 for controls, suggesting that the porosity
introduced by the addition of meshes aided in the faster vancomycin release from the
interior of the scaffold in a proportional manner to that of percent chitosan mesh
incorporation. Despite this, our measured antibiotic release does fall within range of
reported antibiotic elution from CS scaffolds, 3-42 days, as reported in the literature
39,68,69,71,72

. This widely reported elution range is caused by several factors such as amount

of drug loaded and sampling frequency. Taking samples every day compared to certain
intervals will prevent drug build up in the eluent that can lead to high antibiotic data at
later time points 39. While sampling every day does not reflect how elution and fluid
would behave in a wound, it helps give a better idea of the daily drug dose that would be
eluted from a scaffold in vitro.
As indicative by the vancomycin elution, activity against S. aureus was the
longest for control groups, and the shortest for 7% M scaffolds, a result from the
increased porosity with the addition of chitosan mesh. In a previous study vancomycin
elution from scaffolds containing chitosan microspheres were found to be active against
S. aureus for 18 days 39 compared to 10-17 days for 4% and 7% M containing scaffolds.
The discrepancy in activity is a result of the daily elution collection compared to interval
collection. The activity of eluted antibiotic was not within the target 4-6 weeks period for
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antibiotic treatment of orthopaedic wounds, also due to the collection frequency. A
limitation of this work is that scaffolds were not tested in an infected model, but we
suspect that scaffolds loaded with 4% mesh would show extended antibiotic activity and
be helpful in preventing infection in a fracture site.
As reported in a previous study from our group, CS matrix acted as a barrier for
rhBMP-2 release and eliminated typical burst release patterns in the first days as seen in
delivery systems such as collagen sponges 18,39,73. While rhBMP-2 acts on
osteoprogenetor cells that arrive about one week after a fracture, it is also involved in the
early recruitment of mesenchymal stem cells, thus a couple of days delay would be
beneficial in a fracture site74–77. An extended rhBMP-2 elution was seen for all groups
during the study, and elution levels, 0.2-6.19ng/day, and percent recovery, 0.69-1.13%,
were similar to those reported in previous research from CS-chitosan rhBMP-2 loadedmicrosphere scaffolds, 0.18-4.48ng/day and 0.98-1.17% respectively39. The use of
chitosan mesh in the scaffolds resulted in only a slight increase in elution rate, but no
increase in overall recovery of the rhBMP-2 was seen. Despite this, the extended growth
factor elution may be beneficial in fracture wounds because literature has suggested that
extended rhBMP-2 release is better at augmenting fracture healing than a single large
bolus delivery of the growth factor 18,75,78,79. The low recovery of rhBMP-2 after 42 days
indicates that the growth factor is likely being well retained by scaffold components, as
rhBMP-2 is known to bind to calcium based scaffolds, as well as to chitosan materials
due to ionic charges between the chitosan and rhBMP-2 36,57,58. The high
binding/retention to chitosan is supported in this work by our visual detection of the
fluorescently labeled rhBMP-2 on chitosan meshes embedded in CS over 6 weeks. Zhao
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et al. also reported low recovery of rhBMP-2, 8.8%, for CPC-chitosan scaffolds
containing rhBMP-2 loaded alginate microbeads after 20 days, which is comparable to
the recovery, we found for group M, 10.63% 80. The high retention and low release of
BMP-2 in vitro may be similar to physiological growth factor production and perhaps
lead to improved bone filling and formation within large defect areas over time without
the risk of high dosing and over production of bone. The activity of eluted rhBMP-2 was
not determined in vitro due to high osmolality in eluates from the CS degradation, which
interferes with the cellular assay. Thus, future work should evaluate the ability of this
scaffold to stimulate bone growth in vivo. Though not specifically evaluated in this study,
it is anticipated that there would be minimal to no interference of released vancomycin on
the activity of rhBMP-2. This is because only very high levels of vancomycin (1800-3000
µg/mL) have been reported to interfere with rhBMP-2 during the initial release time
points in vitro 39. At these first time points there was little to no rhBMP-2 detected and at
day 3, when rhBMP-2 release was beginning, vancomycin levels were reduced to noninhibitory levels (<1500 µg/ml)39. Thus, another advantage of the delayed release of
BMP-2 is preserving the function of growth factor in the presence of initially high doses
of antibiotics.
Conclusion
This study demonstrated the potential of a CS-chitosan mesh scaffold to be used
as a combination drug delivery device to aid in infection control and new bone growth in
a musculoskeletal wound. Although the calcium lactate did not enhance the binding
between the chitosan mesh and calcium sulfate, it did have an unexpected benefit of
increasing the handleablility of the scaffold before setting, which may be advantageous
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for a surgeon in the operating room. Despite the reduction in mechanical strengths of
scaffolds containing chitosan meshes, the strengths were similar to those of other
reported fiber-reinforced scaffolds, and applicable for non-load bearing fractures.
Additionally, the incorporation of meshes improved the ability of the scaffold to remain
intact under some loading conditions, which is beneficial to prevent scaffold breakage
and delivery of therapeutics to unwanted areas. The inclusion of chitosan-mesh did affect
the vancomycin elution by increasing the rate of elution with increasing mesh percentage.
Likewise, the scaffolds with meshes exhibited shorter duration of bacterial inhibition
compared to controls, but were still effective against S. aureus for over 10 days. The
growth factor elution did not appear to be affected by the different percentages of
chitosan mesh incorporation in part because the rhBMP-2 appeared to remain tightly
bound to the chitosan for the duration of the study. Mixing the mesh into the CS
eliminated the typical burst release of rhBMP-2, and contributed to the continuous and
sustained delivery over 6 weeks. Overall, the incorporation of 4% mesh was more
advantageous with respect to mechanical strength, vancomycin elution and bacterial
inhibition compared to the scaffolds with 7% mesh, and thus it is recommended for use in
future studies.
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CONCLUSIONS

In chapter 2, the study of single and dual loaded antibiotics from a calcium sulfate–
chitosan-nHA composite scaffold showed that the vancomycin elution from the dual
loaded scaffold had the longest inhibition of S. aureus (34 days) compared to all other
groups. In contrast, the amikacin elution was only effective in the inhibition of P.
aeruginosa for 24 hours regardless of scaffold composition. Vancomycin, loaded into the
calcium sulfate matrix part of the scaffold, was more effective at bacterial inhibition and
elimination of S. aureus compared to amikacin because 20x more vancomycin was
incorporated than amikacin. Both the vancomycin and amikacin antibiotic elution showed
a lower burst release from all composite CS-chitosan microspheres on the first day
compared to control scaffolds of CS. Additionally, extended elution from composite
scaffolds was also achieved. These results indicate that 1) vancomycin was successfully
delivered from the CS matrix and remained active for an extended time (27-34 days) 2) a
delayed burst (1 day) and extended low-level therapeutic release (7-42 days above MIC
for P. aeruginosa) was achieved from the amikacin loaded microspheres embedded in CS
matrix. Even though the delayed amikacin release from composite scaffolds was not as
successful for our intended application of antibacterial inhibition, it could be beneficial in
an application where there was a need to deliver therapeutics in stages, rather than at the
same time. This outcome led us to investigate the use of this scaffold with an antibiotic
and a growth factor where reduced burst and extended release are thought to be an ideal
delivery mechanism.

96

The delivery of a growth factor, rhBMP-2, and an antibiotic, vancomycin, was
investigated in chapter 3. Similar to the previous work in chapter 2, the vancomycin was
able to inhibit and kill S. aureus for an extended time (18 days). However, the growth
factor release from chitosan-nHA microspheres embedded in CS matrix was much less
than that released from microspheres alone. The rhBMP-2 release showed a 2 day delay
and extended low level elution throughout 42 days, but activity on W-20-17 mouse
fibroblast cells were unsuccessful in predicting activity due to the high osmolality created
by the dissolution of CS in the eluent. Mock solutions with rhBMP-2 and vancomycin
showed that W-20-17 cells were viable in the presence of vancomycin at varying
concentrations. Additionally, the ALP expression from cells increased with increasing
rhBMP-2 concentrations in mock solutions but decreased in the presence of high
vancomycin concentrations (1800-3600 µg/mL), suggesting that delayed rhBMP-2
release during the first days of high antibiotic release would help minimize the loss of
function of the growth factor. From the mock solution experiment, we determined that
the activity of rhBMP-2 released from composite scaffolds would be difficult to detect in
cell studies. The important outcomes of this work were 1) an extended and active
antibiotic elution from the composite scaffolds 2) a delayed burst and extended rhBMP-2
release from microspheres embedded in the scaffolds 3) eluted levels of rhBMP-2 from
composites might not be high enough to produce a measurable cellular response in vitro.
These findings directed us to investigate other delivery systems that might increase the
level of rhBMP-2 released without compromising the beneficial therapeutic release
kinetics of the scaffold.
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We investigated a calcium sulfate composite with chitosan fiber-mesh to improve the
rhBMP-2 elution, in chapter 4. Based on literature of fiber-reinforced composites we
were also interested to know if any mechanical properties would be gained by the
incorporation of fibers into the composite scaffold. Chitosan lactate, used as a binding
agent, was found to improve the handleability of the scaffold but did not show consistent
results in improving scaffold properties for compression or three-point bend tests.
Overall, the mechanical properties of the scaffolds decreased with increasing percent of
chitosan mesh incorporation. Composite scaffolds with meshes were comparable to
controls in the work required for fracture and the strain energy density, and did have
better break properties because the meshes held the scaffolds together. The elution of the
composite scaffolds changed from a surface type degradation to a bulk degradation,
which indicates increased porosity with the addition of fiber-mesh into the composite.
The vancomycin elution and activity from the composite scaffolds ranged from 10-22
days depending on scaffold composition, but the rhBMP-2 levels did not show a
significant increase in release over the previous study. It was confirmed by fluorescently
labeled rhBMP-2 loaded into composite scaffolds that the growth factor is retained by the
scaffold after 6 weeks.
In summary, incorporation of the chitosan mesh 1) increased the vancomycin elution
from the composite compared, 2) did not increase the rhBMP-2 elution from the
composite, 3) did not improve the mechanical strength of the scaffolds 4) kept the
scaffold intact during mechanical tests, 5) changed the degradation of the scaffold. While
these results are interesting, further optimization on chitosan fiber-mesh is needed to
control elution and degradation. Additionally, there may be a potential advantage of the
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retention and low elution of rhBMP-2 from the scaffold. It is possible that this release
would be similar to the natural biological response of BMP-2 since is normally present in
bone tissue and active as necessary throughout the bone regeneration process. Evaluation
in a small animal model would be necessary to investigate this further.
In conclusion, these experiments demonstrate partial achievement of our original
hypothesis to show adequate antibiotic and growth factor elution for infection control and
cellular indication of active growth factor. We were able to demonstrate extended
antibiotic and growth factor elution, but we were only able to evaluate the antibiotic
activity and were not able to increase the growth factor elution or evaluate the growth
factor activity in vitro. While additional work is needed to improve growth factor release,
the indication that rhBMP-2 remains in the scaffold over 6 weeks and is being slowly
released throughout the study suggest that in vivo there is a potential to stimulate bone
growth over an extended time frame. The use of a chitosan fiber-mesh may be
advantageous over chitosan microspheres because they provide a path by which elution,
degradation, and tissue ingrowth could occur. The ease of fabrication of composite
scaffolds, elution results and mechanical tests indicate that using this scaffold could
prevent the need for supraphysiological doses of growth factor, deliver sustained active
antibiotic, maintain a 3D structure during wound healing, and be customizable by the
surgeon in the operating room. Thus, development of a composite ceramic-degradable
polymer device does demonstrate unique properties and advantages over other scaffold
systems for use as a dual delivery device for use in large and infected musculoskeletal
fractures.
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RECOMMENDATIONS FOR FUTURE WORK
A challenge we faced in this work was detecting the activity of rhBMP-2 in vitro. We
attempted filtering, diluting and dialyzing our elution samples to remove the free calcium
and sulfate ions. However, we were unsuccessful because, the eluents continued to be
overwhelmed by the increased osmolality from CS degradation in cell culture, or the
growth factor was diluted too low to stimulate any kind of response. We also tested an
agarose overlay method with eluents on filter papers, but again we were unsuccessful to
establish a robust method to detect lower levels of activity. Even if we could have
performed the cellular work, it is doubtful that any response would have been achieved
since the levels of rhBMP-2 eluted were below the typical detection limit. Thus, to
overcome this limitation of our work, in vivo testing is needed. Using a soft tissue pouch
model in a rat or mouse, the osteoinductive properties of the scaffold could be evaluated.
A small animal model, such as a rabbit radial model, with a critical size defect could
evaluate the ability to grow new bone into a defect area. Likewise, an infected-defect in a
rabbit radius model would be necessary to determine both the antibiotic and regenerative
properties of the graft.
Additionally, the composition of the scaffold could be further investigated. Chitosan
nanospheres could be evaluated in place of the microspheres, or chitosan fibers in place
of the fiber-mesh. Or the method of scaffold composition could be altered, such as
chitosan fibers pre-wet with chitosan lactate for better integration with CS. Composite
ceramic material could also be investigated instead of CS alone. The delivery properties
of other therapeutic agents should also be investigated because ideally, this scaffold
would be customizable with various antibiotics such as daptomycin, linezolid,
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tobramycin, gentamicin or cefazolin or growth factors, such as BMP-7 or vascular
endothelial growth factor depending on the need of the patient. Further in vitro testing
could also be carried out with other bacteria such as Escherichia coli, Staphylococcus
epidermidis or Streptococcus pyogenes to determine effectiveness against a broader
spectrum of infection causing agents.

101

REFERENCES
1. Giannoudis P V, Dinopoulos H, Tsiridis E. Bone substitutes: an update. Injury.
2005;36 Suppl 3:S20–7.
2. Nair MB, Kretlow JD, Mikos AG, Kasper FK. Infection and tissue engineering in
segmental bone defects--a mini review. Curr. Opin. Biotechnol. Elsevier Ltd;
2011;22:721–5.
3. Dawson JI, Oreffo ROC. Bridging the regeneration gap: stem cells, biomaterials and
clinical translation in bone tissue engineering. Arch. Biochem. Biophys. 2008;473:124–
31.
4. Kretlow JD, Mikos AG. Review: mineralization of synthetic polymer scaffolds for
bone tissue engineering. Tissue Eng. Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd
Floor New Rochelle, NY 10801 USA; 2007;13:927–38.
5. Andersson GBJ, Bouchard J, Bozic KJ. The Burden of Musculoskeletal Disease in the
United States. Burd. Musculoskelet. Dis. United States. Rosemont, IL: American
Academy of Orthopaedic Surgeons; 2011.
6. Falanga V. The chronic wound: Impaired healing and solutions in the context of
wound bed preparation. Blood Cells, Mol. Dis. 2004;32:88–94.
7. Skinner H. CURRENT Diagnosis & Treatment in Orthopedics. 4th ed. Skinner HB,
editor. Lange Medical Books/McGraw Hill; 2010.
8. Murray CK, Wilkins K, Molter NC, Yun HC, Dubick MA, Spott MA, et al. Infections
in combat casualties during Operations Iraqi and Enduring Freedom. J. Trauma.
2009;66:S138–44.
9. El-Husseiny M, Patel S, MacFarlane RJ, Haddad FS. Biodegradable antibiotic delivery
systems. J. Bone Joint Surg. Br. 2011;93:151–7.
10. Thomas M V, Puleo DA. Infection, inflammation, and bone regeneration: a
paradoxical relationship. J. Dent. Res. 2011;90:1052–61.
11. Owens BD, Kragh JF, Macaitis J, Svoboda SJ, Wenke JC. Characterization of
extremity wounds in Operation Iraqi Freedom and Operation Enduring Freedom. J.
Orthop. Trauma. 2007;21:254–7.
12. Murray CK, Hsu JR, Solomkin JS, Keeling JJ, Andersen RC, Ficke JR, et al.
Prevention and management of infections associated with combat-related extremity
injuries. J. Trauma. 2008;64:S239–51.
13. Boateng JS, Matthews KH, Stevens HNE, Eccleston GM. Wound healing dressings
and drug delivery systems: A review. J. Pharm. Sci. 2008. p. 2892–923.
14. Wenke JC, Owens BD, Svoboda SJ, Brooks DE. Effectiveness of commerciallyavailable antibiotic-impregnated implants. J. Bone Joint Surg. Br. 2006;88:1102–4.
15. Zalavras CG, Patzakis MJ, Holtom PD, Sherman R. Management of open fractures.
Infect. Dis. Clin. North Am. 2005;19:915–29.

102

16. Anderson A, Miller AD, Bookstaver B. Antimicrobial prophylaxis in open lower
extremity fractures. Open Access Emerg. Med. 2011;3:7–11.
17. Phillips JE. The incidence of deep prosthetic infections in a specialist orthopaedic
hospital: A 15-YEAR PROSPECTIVE SURVEY. J. Bone Jt. Surg. - Br. Vol. 2006;88B:943–8.
18. Patzakis MJ, Wilkins J. Factors influencing infection rate in open fracture wounds.
Clin. Orthop. Relat. Res. 1989;36–40.
19. Wenke JC, Guelcher SA. Dual delivery of an antibiotic and a growth factor addresses
both the microbiological and biological challenges of contaminated bone fractures.
Expert Opin. Drug Deliv. 2011;8:1555–69.
20. Johnson EN, Burns TC, Hayda RA, Hospenthal DR, Murray CK. Infectious
complications of open type III tibial fractures among combat casualties. Clin. Infect. Dis.
2007;45:409–15.
21. Hatzenbuehler J, Pulling TJ. Diagnosis and management of osteomyelitis. Am. Fam.
Physician. 2011;84:1027–33.
22. Hogan A, Heppert VG, Suda AJ. Osteomyelitis. Arch. Orthop. Trauma Surg.
2013;133:1183–96.
23. Gentry LO. Management of osteomyelitis. Int. J. Antimicrob. Agents. 1997;9:37–42.
24. Kobayashi N, Procop GW, Krebs V, Kobayashi H, Bauer TW. Molecular
identification of bacteria from aseptically loose implants. Clin. Orthop. Relat. Res.
2008;466:1716–25.
25. Bertesteanu S, Triaridis S, Stankovic M, Lazar V, Chifiriuc MC, Vlad M, et al.
Polymicrobial wound infections: Pathophysiology and current therapeutic approaches.
Int. J. Pharm. Elsevier B.V.; 2014;463:119–26.
26. Zalavras CG, Marcus RE, Levin LS, Patzakis MJ. Management of open fractures and
subsequent complications. Instr. Course Lect. 2008;57:51–63.
27. Zilberman M, Elsner JJ. Antibiotic-eluting medical devices for various applications.
J. Control. Release. 2008;130:202–15.
28. Jain AK, Panchagnula R. Skeletal drug delivery systems. Int. J. Pharm. 2000;206:1–
12.
29. Harwood PJ, Newman JB, Michael ALR. (ii) An update on fracture healing and nonunion. Orthop. Trauma. 2010;24:9–23.
30. AI-Aql ZS, Alagl AS, Graves DT, Gerstenfeld LC, Einhorn TA. Molecular
Mechanisms Controlling Bone Formation during Fracture Healing and Distraction
Osteogenesis. J. Dent. Res. 2008;87:107–18.
31. Ketonis C, Hickok N, Parvizi J. Antimicrobial implants and bone allografts : new
uses for old antibiotics. In: Méndez-Vilas A, editor. Sci. against Microb. Pathog.
Commun. Curr. Res. Technol. Adv. 2nd ed. Formatex Research Center; 2011. p. 469–82.

103

32. Bi L, Hu Y, Fan H, Meng G, Liu J, Li D, et al. Treatment of Contaminated Bone
Defects With Clindamycin- Reconstituted Bone Xenograft-Composites. J. Biomed.
Mater. Res. 2007;418–27.
33. Vaccaro AR. The role of the osteoconductive scaffold in synthetic bone graft.
Orthopedics. 2002;25:s571–8.
34. Nelson CL. The current status of material used for depot delivery of drugs. Clin.
Orthop. Relat. Res. 2004;427:72–8.
35. Jahangir AA, Nunley RM, Mehta S, Sharan A. Bone-graft substitutes in orthopaedic
surgery. AAOS Now. 2008;2:5–9.
36. Roberts TT, Rosenbaum AJ. Bone grafts, bone substitutes and orthobiologics: the
bridge between basic science and clinical advancements in fracture healing.
Organogenesis. 2012;8:114–24.
37. Bucholz RW. Nonallograft osteoconductive bone graft substitutes. Clin. Orthop.
Relat. Res. 2002;44–52.
38. McLaren AC. Alternative Materials to Acrylic Bone Cement for Delivery of Depot
Antibiotics in Orthopaedic Infections. Clin. Orthop. Relat. Res. 2004;101–6.
39. Peters CL, Hines JL, Bachus KN, Craig M a., Bloebaum RD. Biological effects of
calcium sulfate as a bone graft substitute in ovine metaphyseal defects. J. Biomed. Mater.
Res. - Part A. 2006;76:456–62.
40. Ricci JL, Alexander H, Nadkarni P, Hawkins M, Turner J, Rosenblum S, et al.
Biological Mechanisms of Calcium Sulfate Replacement by Bone. In: Davies JE, editor.
Bone Eng. Toronto, Canada: EM Squared; 2000. p. 332–44.
41. Thomas M V, Puleo DA. Calcium sulfate: Properties and clinical applications. J.
Biomed. Mater. Res. B. Appl. Biomater. 2009;88:597–610.
42. Mousset B, Benoit MA, Delloye C, Bouillet R, Gillard J. Biodegradable implants for
potential use in bone infection. An in vitro study of antibiotic-loaded calcium sulphate.
Int. Orthop. 1995;19:157–61.
43. Aiken SS, Cooper JJ, Florance H, Robinson MT, Michell S. Local release of
antibiotics for surgical site infection management using high-purity calcium sulfate: an in
vitro elution study. Surg. Infect. (Larchmt). 2015;16:54–61.
44. Mackey D, Varlet A, Debeaumont D. Antibiotic loaded plaster of Paris pellets: an in
vitro study of a possible method of local antibiotic therapy in bone infection. Clin.
Orthop. Relat. Res. 1982;263–8.
45. Santschi EM, McGarvey L. In Vitro Elution of Gentamicin from Plaster of Paris
Beads. Vet. Surg. 2003;32:128–33.
46. Thomas DB, Brooks DE, Bice TG, DeJong ES, Lonergan KT, Wenke JC.
Tobramycin-impregnated calcium sulfate prevents infection in contaminated wounds.
Clin. Orthop. Relat. Res. 2005;441:366–71.
47. Mckee MD, Wild LM, Schemitsch EH, Waddell JP. The Use of an Antibiotic104

Impregnated , Osteoconductive , Bioabsorbable Bone Substitute in the Treatment of
Infected Long Bone Defects : Early Results of a Prospective Trial. Int. Orthop.
2002;16:622–7.
48. Hanssen AD. Local antibiotic delivery vehicles in the treatment of musculoskeletal
infection. Clin. Orthop. Relat. Res. 2005;91–6.
49. Cowan CM, Soo C, Ting K, Wu B. Evolving concepts in bone tissue engineering.
Curr Top Dev Biol. Elsevier Inc; 2005;66:239–84.
50. Habraken WJEM, Wolke JGC, Jansen JA. Ceramic composites as matrices and
scaffolds for drug delivery in tissue engineering. Adv. Drug Deliv. Rev. 2007;59:234–48.
51. Suzuki A, Terai H, Toyoda H, Namikawa T, Yokota Y, Tsunoda T, et al. A
biodegradable delivery system for antibiotics and recombinant human bone
morphogenetic protein-2: A potential treatment for infected bone defects. J. Orthop. Res.
2006;24:327–32.
52. Liu S-J, Chi P-S, Lin S-S, Ueng SW-N, Chan E-C, Chen J-K. Novel solvent-free
fabrication of biodegradable poly-lactic-glycolic acid (PLGA) capsules for antibiotics
and rhBMP-2 delivery. Int. J. Pharm. 2007;330:45–53.
53. Li X, Xu J, Filion TM, Ayers DC, Song J. pHEMA-nHA Encapsulation and Delivery
of Vancomycin and rhBMP-2 Enhances its Role as a Bone Graft Substitute. Clin. Orthop.
Relat. Res. 2013;471:2540–7.
54. Ambrose CG, Clyburn TA, Louden K, Joseph J, Wright J, Gulati P, et al. Effective
treatment of osteomyelitis with biodegradable microspheres in a rabbit model. Clin.
Orthop. Relat. Res. 2004;293–9.
55. Li B, Brown K V, Wenke JC, Guelcher S a. Sustained release of vancomycin from
polyurethane scaffolds inhibits infection of bone wounds in a rat femoral segmental
defect model. J. Control. Release. Elsevier B.V.; 2010;145:221–30.
56. Meani E, Romanò C, Crosby L, Hofmann G, Calonego G, editors. Infection and
Local Treatment in Orthopedic Surgery. Springer Berlin Heidelberg; 2007.
57. Geiger M. Collagen sponges for bone regeneration with rhBMP-2. Adv. Drug Deliv.
Rev. 2003;55:1613–29.
58. Guelcher SA, Brown K V, Li B, Guda T, Lee B-H, Wenke JC. Dual-purpose bone
grafts improve healing and reduce infection. J. Orthop. Trauma. 2011;25:477–82.
59. Bhattarai N, Gunn J, Zhang M. Chitosan-based hydrogels for controlled, localized
drug delivery. Adv. Drug Deliv. Rev. Elsevier B.V.; 2010;62:83–99.
60. Khor E, Lim LY. Implantable applications of chitin and chitosan. Biomaterials.
2003;24:2339–49.
61. Yuan Y, Chesnutt BM, Utturkar G, Haggard WO, Yang Y, Ong JL, et al. The effect
of cross-linking of chitosan microspheres with genipin on protein release. Carbohydr.
Polym. 2007;68:561–7.
62. Reves BT, Bumgardner JD, Cole JA, Yang Y, Haggard WO. Lyophilization to
105

improve drug delivery for chitosan-calcium phosphate bone scaffold construct: a
preliminary investigation. J. Biomed. Mater. Res. B. Appl. Biomater. 2009;90:1–10.
63. Dash M, Chiellini F, Ottenbrite RM, Chiellini E. Chitosan—A versatile semisynthetic polymer in biomedical applications. Prog. Polym. Sci. Elsevier Ltd;
2011;36:981–1014.
64. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosanbased micro- and nanoparticles in drug delivery. J. Control. Release. 2004;100:5–28.
65. Khor E. Chitin: Fulfilling a Biomaterials Promise. 1st ed. Elsevier Science; 2001.
66. Di Martino A, Sittinger M, Risbud M V. Chitosan: a versatile biopolymer for
orthopaedic tissue-engineering. Biomaterials. 2005;26:5983–90.
67. Bumgardner JD, Wiser R, Gerard PD, Bergin P, Chestnutt B, Marin M, et al.
Chitosan: potential use as a bioactive coating for orthopaedic and craniofacial/dental
implants. J. Biomater. Sci. Polym. Ed. 2003;14:423–38.
68. Pillai CKS, Paul W, Sharma CP. Chitin and chitosan polymers: Chemistry, solubility
and fiber formation. Prog. Polym. Sci. 2009;34:641–78.
69. Shi C, Zhu Y, Ran X, Wang M, Su Y, Cheng T. Therapeutic potential of chitosan and
its derivatives in regenerative medicine. J. Surg. Res. 2006;133:185–92.
70. Chesnutt BM, Viano AM, Yuan Y, Yang Y, Guda T, Appleford MR, et al. Design
and characterization of a novel chitosan/nanocrystalline calcium phosphate composite
scaffold for bone regeneration. J. Biomed. Mater. Res. A. 2009;88:491–502.
71. Venkatesan J, Kim S-K. Chitosan composites for bone tissue engineering--an
overview. Mar. Drugs. 2010;8:2252–66.
72. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, et al. Chitosan
microspheres as a potential carrier for drugs. Int. J. Pharm. 2004;274:1–33.
73. Keaveny TM, Hayes WC. Mechanical Properties of Cortical and Trabecular Bone.
Bone. CRC Press; 1993.
74. Xu HHK, Simon CG. Fast setting calcium phosphate-chitosan scaffold: mechanical
properties and biocompatibility. Biomaterials. 2005;26:1337–48.
75. Zhang Y, Ni M, Zhang M, Ratner B. Calcium phosphate-chitosan composite
scaffolds for bone tissue engineering. Tissue Eng. 2003;9:337–45.
76. Cui X, Zhang B, Wang Y, Gao Y. Effects of Chitosan-Coated Pressed Calcium
Sulfate Pellet Combined With Recombinant Human Bone Morphogenetic Protein 2 on
Restoration of Segmental Bone Defect. J. Craniofac. Surg. :459–65.
77. Cho BC, Kim TG, Yang JD, Chung HY, Park JW, Kwon IC, et al. Effect of calcium
sulfate-chitosan composite: pellet on bone formation in bone defect. J. Craniofac. Surg.
2005;16:213–24; discussion 225–7.
78. Beenken KE, Smith JK, Skinner RA, Mclaren SG, Bellamy W, Gruenwald MJ, et al.
Chitosan coating to enhance the therapeutic efficacy of calcium sulfate-based antibiotic

106

therapy in the treatment of chronic osteomyelitis. J. Biomater. Appl. 2014;29:514–23.
79. Sundaram MN, Sowmya S, Deepthi S, Bumgardener JD, Jayakumar R. Bilayered
construct for simultaneous regeneration of alveolar bone and periodontal ligament.
2015;963:1–10.
80. Zhao L, Burguera EF, Xu HHK, Amin N, Ryou H, Arola DD. Fatigue and human
umbilical cord stem cell seeding characteristics of calcium phosphate–chitosan–
biodegradable fiber scaffolds. Biomaterials. 2010;31:840–7.
81. Pan Z, Jiang P, Fan Q, Ma B, Cai H. Mechanical and biocompatible influences of
chitosan fiber and gelatin on calcium phosphate cement. J. Biomed. Mater. Res. B. Appl.
Biomater. 2007;82:246–452.
82. Weir MD, Xu HHK. Human bone marrow stem cell-encapsulating calcium phosphate
scaffolds for bone repair. Acta Biomater. 2010;6:4118–26.
83. Lian Q, Li D-C, He J-K, Wang Z. Mechanical properties and in-vivo performance of
calcium phosphate cement-chitosan fibre composite. Proc. Inst. Mech. Eng. H.
2008;222:347–53.
84. Bao C, Chen W, Weir MD, Thein-Han W, Xu HHK. Effects of electrospun
submicron fibers in calcium phosphate cement scaffold on mechanical properties and
osteogenic differentiation of umbilical cord stem cells. Acta Biomater. 2011;7:4037–44.
85. Ge Z. Hydroxyapatite–chitin materials as potential tissue engineered bone substitutes.
Biomaterials. 2004;25:1049–58.
86. Cho BC, Chung HY, Lee DG, Yang JD, Park JW, Roh KH, et al. The effect of
chitosan bead encapsulating calcium sulfate as an injectable bone substitute on
consolidation in the mandibular distraction osteogenesis of a dog model. J. Oral
Maxillofac. Surg. 2005;63:1753–64.
87. Nelson CL, McLaren SG, Skinner RA, Smeltzer MS, Thomas JR, Olsen KM. The
treatment of experimental osteomyelitis by surgical debridement and the implantation of
calcium sulfate tobramycin pellets. J. Orthop. Res. 2002;20:643–7.
88. Rathbone CR, Cross JD, Brown K V, Murray CK, Wenke JC. Effect of various
concentrations of antibiotics on osteogenic cell viability and activity. J. Orthop. Res.
2011;29:1070–4.
89. Edin ML, Miclau T, Lester GE, Lindsey RW, Dahners LE. Effect of cefazolin and
vancomycin on osteoblasts in vitro. Clin. Orthop. Relat. Res. 1996;245–51.
90. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few
years. Chest. 2001;119:397S – 404S.
91. Atilla A, Boothe HW, Tollett M, Duran S, Diaz DC, Sofge J, et al. In vitro elution of
amikacin and vancomycin from impregnated plaster of Paris beads. Vet. Surg.
2010;39:715–21.
92. Thomas LA, Bizikova T, Minihan AC. In vitro elution and antibacterial activity of
clindamycin, amikacin, and vancomycin from R-gel polymer. Vet. Surg. 2011;40:774–

107

80.
93. Lazzarini L, Mader JT, Calhoun JH. Osteomyelitis in long bones. J. Bone Joint Surg.
Am. 2004;86-A:2305–18.
94. Lew DP, Waldvogel FA. Osteomyelitis. N. Engl. J. Med. 1997;336:999–1007.
95. Carano RAD, Filvaroff EH. Angiogenesis and bone repair Bone healing. 2003;8:980–
9.
96. Granjeiro JM, Oliveira RC, Bustos-Valenzuela JC, Sogayar MC, Taga R. Bone
morphogenetic proteins: from structure to clinical use. Braz. J. Med. Biol. Res.
2005;38:1463–73.
97. Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of
bone. Biology and clinical applications. J. Bone Joint Surg. Am. 2002;84-A:1032–44.
98. Reddi AH. Bone morphogenetic proteins: from basic science to clinical applications.
J. Bone Joint Surg. Am. 2001;83-A Suppl:S1–6.
99. Chang JH. Bone-building scaffolds become smarter. SPIE Newsroom. 2007;10–1.
100. Seeherman H, Li R, Wozney J. A review of preclinical program development for
evaluating injectable carriers for osteogenic factors. J. Bone Joint Surg. Am. 2003;85-A
Suppl:96–108.
101. Schmitt JM, Hwang K, Winn SR, Hollinger JO. Bone morphogenetic proteins: An
update on basic biology and clinical relevance. J. Orthop. Res. 1999;17:269–78.
102. Wang Y, Wang X, Li H, Xue D, Shi Z, Qi Y, et al. Assessing the character of the
rhBMP-2- and vancomycin-loaded calcium sulphate composites in vitro and in vivo.
Arch. Orthop. Trauma Surg. 2011;131:991–1001.
103. Skelly JD, Lange J, Filion TM, Li X, Ayers DC, Song J. Vancomycin-bearing
Synthetic Bone Graft Delivers rhBMP-2 and Promotes Healing of Critical Rat Femoral
Segmental Defects. Clin. Orthop. Relat. Res. 2014;4015–23.
104. Strobel C, Bormann N, Kadow-Romacker A, Schmidmaier G, Wildemann B.
Sequential release kinetics of two (gentamicin and BMP-2) or three (gentamicin, IGF-I
and BMP-2) substances from a one-component polymeric coating on implants. J. Control.
Release. 2011;156:37–45.
105. Glatt V, Kwong FN, Park K, Parry N, Griffin D, Vrahas M, et al. Ability of
recombinant human bone morphogenetic protein 2 to enhance bone healing in the
presence of tobramycin: evaluation in a rat segmental defect model. J. Orthop. Trauma.
2009;23:693–701.

108

